Skip to main content
Saye Khoo

Professor Saye Khoo
MB,BS, MRCP, DTM&H, FRCP, MD, Diploma in Epidemiology

Contact

S.H.Khoo@liverpool.ac.uk

+44 (0)151 794 5560

Publications

Selected publications

  1. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study (Journal article - 2022)
  2. An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2 (Journal article - 2022)
  3. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study (Journal article - 2021)
  4. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) (Journal article - 2019)
  5. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial (Journal article - 2016)
  6. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries (Journal article - 2014)
  7. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. (Journal article - 1999)
  8. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial (Journal article - 2022)
  9. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial (Journal article - 2022)
What type of publication do you want to show?

2024

Population pharmacokinetic modeling of paired plasma-breast milk lamivudine data for estimation of infant exposure in breastfeeding mother-infant pairs.

Ojara, F. W., Kawuma, A. N., Nakalema, S., Kyohairwe, I., Nakijoba, R., Lamorde, M., . . . Waitt, C. (2024). Population pharmacokinetic modeling of paired plasma-breast milk lamivudine data for estimation of infant exposure in breastfeeding mother-infant pairs.. CPT: pharmacometrics & systems pharmacology. doi:10.1002/psp4.13274

DOI
10.1002/psp4.13274
Journal article

Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.

Nightingale, S., Dreyer, A. J., Thomas, K. G. F., van Zyl, G., Decloedt, E., Naude, P. J. W., . . . Joska, J. A. (2024). Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study.. The lancet. HIV, 11(10), e680-e689. doi:10.1016/s2352-3018(24)00209-1

DOI
10.1016/s2352-3018(24)00209-1
Journal article

Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study.

Joseph Davey, D., Dadan, S., Bheemraj, K., Waitt, C., Khoo, S., Myer, L., . . . Orrell, C. (2024). Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study.. Antiviral research, 231, 106014. doi:10.1016/j.antiviral.2024.106014

DOI
10.1016/j.antiviral.2024.106014
Journal article

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.

Harris, V., Holmes, J., Gbinigie-Thompson, O., Rahman, N. M., Richards, D. B., Hayward, G., . . . PANORAMIC Trial Collaborative Group. (2024). Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.. The Lancet. Infectious diseases, S1473-3099(24)00431-6. doi:10.1016/s1473-3099(24)00431-6

DOI
10.1016/s1473-3099(24)00431-6
Journal article

Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.

Png, M. E., Harris, V., Grabey, J., Hart, N. D., Jani, B. D., Butler, D., . . . PANORAMIC Trial Collaborators. (2024). Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial.. The British journal of general practice : the journal of the Royal College of General Practitioners, 74(745), e570-e579. doi:10.3399/bjgp.2023.0444

DOI
10.3399/bjgp.2023.0444
Journal article

Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.

Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., . . . Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.. The Journal of antimicrobial chemotherapy, dkae232. doi:10.1093/jac/dkae232

DOI
10.1093/jac/dkae232
Journal article

Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.

Else, L. J., Dickinson, L., Edick, S., Zyhowski, A., Ho, K., Meyn, L., . . . Brand, R. M. (2024). Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing.. The Journal of antimicrobial chemotherapy, 79(7), 1597-1605. doi:10.1093/jac/dkae147

DOI
10.1093/jac/dkae147
Journal article

A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.

Challenger, E., Dilly-Penchala, S., Hale, C., Fitzgerald, R., Reynolds, H., Chiong, J., . . . Else, L. (2024). A novel LC-MS/MS method for the determination of favipiravir ribofuranosyl-5'-triphosphate (T-705-RTP) in human peripheral mononuclear cells.. Journal of pharmaceutical and biomedical analysis, 245, 116155. doi:10.1016/j.jpba.2024.116155

DOI
10.1016/j.jpba.2024.116155
Journal article

Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.

Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2024). Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 15(1), 2918. doi:10.1038/s41467-024-47320-6

DOI
10.1038/s41467-024-47320-6
Journal article

Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.

van der Wekken-Pas, L., Nassiwa, S., Malaba, T., Lamorde, M., Myer, L., Waitt, C., . . . Colbers, A. (2024). Comparison of dolutegravir- and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV; a DolPHIN2 substudy.. AIDS (London, England). doi:10.1097/qad.0000000000003852

DOI
10.1097/qad.0000000000003852
Journal article

2023

A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin

Rametse, C. L., Webb, E., Herrera, C., Alinde, B., Besethi, A., Motaung, B., . . . CHAPS, C. (2023). A randomized clinical trial of on-demand oral pre-exposure prophylaxis does not modulate lymphoid/myeloid HIV target cell density in the foreskin. AIDS, 37(11), 1651-1659. doi:10.1097/QAD.0000000000003619

DOI
10.1097/QAD.0000000000003619
Journal article

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Gbinigie, O., Ogburn, E., Allen, J., Dorward, J., Dobson, M., Madden, T. -A., . . . Butler, C. C. (2023). Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ OPEN, 13(8). doi:10.1136/bmjopen-2022-069176

DOI
10.1136/bmjopen-2022-069176
Journal article

Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

Herrera, C., Serwanga, J., Else, L., Limakatso, L., Opoka, D., Ssemata, A. S., . . . CHAPS. (2023). Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial. EBIOMEDICINE, 93. doi:10.1016/j.ebiom.2023.104648

DOI
10.1016/j.ebiom.2023.104648
Journal article

Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS

Thompson, B., Dilly-Penchala, S., Amara, A., Reynolds, H., Khoo, S., & Else, L. (2023). Application of novel plasma separation filter cards for quantification of nucleoside/nucleotide reverse transcriptase inhibitor di/triphosphates in dried blood spot using LC-MS. BIOANALYSIS, 15(13), 739-756. doi:10.4155/bio-2023-0057

DOI
10.4155/bio-2023-0057
Journal article

Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.

BUZIBYE, A. L. L. A. N., Wools-Kaloustian, K., Olagunju, A., Twinomuhwezi, E., Yiannoutsos, C., Owen, A., . . . Kiragga, A. (2023). Relating CYP2B6 Genotype and EFV Resistance Among Women Living With HIV With High Viremia in Uganda: A Nested Cross-Sectional Study.. AIDS Research and Therapy. doi:10.1186/s12981-023-00514-2

DOI
10.1186/s12981-023-00514-2
Journal article

Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.

Maddox, V., Reynolds, C., Amara, A., Else, L., Brailsford, S. R., Khoo, S., & Harvala, H. (2023). Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 28(11). doi:10.2807/1560-7917.es.2023.28.11.2300135

DOI
10.2807/1560-7917.es.2023.28.11.2300135
Journal article

Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122

DOI
10.1097/QAI.0000000000003122
Journal article

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Butler, C. C., Hobbs, F. D. R., Gbinigie, O. A., Rahman, N. M., Hayward, G., Richards, D. B., . . . Little, P. (2023). Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. LANCET, 401(10373), 281-293. doi:10.1016/S0140-6736(22)02597-1

DOI
10.1016/S0140-6736(22)02597-1
Journal article

2022

Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. CLINICAL PHARMACOLOGY & THERAPEUTICS, 112(6), 1191-1200. doi:10.1002/cpt.2646

DOI
10.1002/cpt.2646
Journal article

Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials

Venter, F., Sokhela, S., Calmy, A., Siedner, M. J., Khoo, S., Clayden, P., . . . Collins, S. (2022). Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials. AIDS, 36(13), 1900-1901. doi:10.1097/QAD.0000000000003310

DOI
10.1097/QAD.0000000000003310
Journal article

Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.

Baruch, J., Rojek, A., Kartsonaki, C., Vijayaraghavan, B. K. T., Gonçalves, B. P., Pritchard, M. G., . . . ISARIC Clinical Characterisation Group. (2022). Symptom-based case definitions for COVID-19: Time and geographical variations for detection at hospital admission among 260,000 patients.. Influenza and other respiratory viruses, 16(6), 1040-1050. doi:10.1111/irv.13039

DOI
10.1111/irv.13039
Journal article

High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis

McCallum, A. D., Pertinez, H. E., Chirambo, A. P., Sheha, I., Chasweka, M., Malamba, R., . . . Mwandumba, H. C. (2022). High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis. CLINICAL INFECTIOUS DISEASES, 75(9), 1520-1528. doi:10.1093/cid/ciac228

DOI
10.1093/cid/ciac228
Journal article

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmad, S., Edwards, C. J., . . . Vyas, A. (2022). Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases. doi:10.1016/s1473-3099(22)00644-2

DOI
10.1016/s1473-3099(22)00644-2
Journal article

Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study

Vink, E., Davis, C., MacLean, A., Pascall, D., McDonald, S. E., Gunson, R., . . . Ho, A. (2022). Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac531

DOI
10.1093/ofid/ofac531
Journal article

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Butler, C., Hobbs, R., Gbinigie, O., Rahman, N. M., Hayward, G., Richards, D., . . . Little, P. (2022). Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial.

Journal article

72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study

Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., . . . Khoo, S. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. LANCET HIV, 9(8), E534-E543. doi:10.1016/S2352-3018(22)00173-4

DOI
10.1016/S2352-3018(22)00173-4
Journal article

'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda

Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). 'I fear my partner will abandon me': the intersection of late initiation of antenatal care in pregnancy and poor ART adherence among women living with HIV in South Africa and Uganda. BMC PREGNANCY AND CHILDBIRTH, 22(1). doi:10.1186/s12884-022-04896-5

DOI
10.1186/s12884-022-04896-5
Journal article

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria

Nwogu, J. N., Ngene, S. O., Babalola, C. P., Olagunju, A., Owen, A., Khoo, S. H., . . . Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00462-3

DOI
10.1186/s12981-022-00462-3
Journal article

Approaches to accelerating the study of new antiretrovirals in pregnancy

Abrams, E. J., Calmy, A., Fairlie, L., Mahaka, I. C., Chimula, L., Flynn, P. M., . . . Siberry, G. K. (2022). Approaches to accelerating the study of new antiretrovirals in pregnancy. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25. doi:10.1002/jia2.25916

DOI
10.1002/jia2.25916
Journal article

Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy

Brummel, S. S., Stringer, J., Mills, E., Tierney, C., Caniglia, E. C., Colbers, A., . . . Lockman, S. (2022). Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 25. doi:10.1002/jia2.25917

DOI
10.1002/jia2.25917
Journal article

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020)

Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111

DOI
10.1093/jac/dkac111
Journal article

<i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda

Alhassan, Y., Twimukye, A., Malaba, T., Myer, L., Waitt, C., Lamorde, M., . . . Taegtmeyer, M. (2022). <i>"It's only fatness, it doesn't kill"</i>: a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda. BMC WOMENS HEALTH, 22(1). doi:10.1186/s12905-022-01814-x

DOI
10.1186/s12905-022-01814-x
Journal article

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

Ochanda, P. N., Lamorde, M., Kintu, K., Wang, D., Chen, T., Malaba, T., . . . Khoo, S. (2022). A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS RESEARCH AND THERAPY, 19(1). doi:10.1186/s12981-022-00446-3

DOI
10.1186/s12981-022-00446-3
Journal article

Total and Unbound Doravirine Concentrations and Viral Suppression in CSF

Tiraboschi, J., Scevola, S., Penchala, S. D., Challenger, E., Else, L., Prieto, P., . . . Podzamczer, D. (2022). Total and Unbound Doravirine Concentrations and Viral Suppression in CSF. CLINICAL INFECTIOUS DISEASES, 74(10), 1855-1858. doi:10.1093/cid/ciab835

DOI
10.1093/cid/ciab835
Journal article

Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions

Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., . . . Khoo, S. (2022). Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. ANNALS OF INTERNAL MEDICINE, 175(5), 744-+. doi:10.7326/M22-0281

DOI
10.7326/M22-0281
Journal article

Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

FitzGerald, R., Dickinson, L., Else, L., Fletcher, T., Hale, C., Amara, A., . . . Khoo, S. (2022). Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES. doi:10.1093/cid/ciac199

DOI
10.1093/cid/ciac199
Journal article

Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection

Marzolini, C., Gibbons, S., van Oosterhout, J. J., & Khoo, S. (2022). Drug-Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection. CLINICAL PHARMACOKINETICS, 61(3), 339-346. doi:10.1007/s40262-021-01098-8

DOI
10.1007/s40262-021-01098-8
Journal article

Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019

Harvala, H., Reynolds, C., Ijaz, S., Maddox, V., Penchala, S. D., Amara, A., . . . Khoo, S. (2022). Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP/PEP) among blood donors: a pilot study, England June 2018 to July 2019. SEXUALLY TRANSMITTED INFECTIONS, 98(2), 132-135. doi:10.1136/sextrans-2021-054981

DOI
10.1136/sextrans-2021-054981
Journal article

Fluvoxamine for the treatment of COVID-19

Marzolini, C., Marra, F., Boyle, A., Khoo, S., & Back, D. J. (2022). Fluvoxamine for the treatment of COVID-19. LANCET GLOBAL HEALTH, 10(3), E331. Retrieved from https://www.webofscience.com/

Journal article

Circulating microparticles are increased amongst people presenting with HIV and advanced immune suppression in Malawi and correlate closely with arterial stiffness: a nested case control study

Kelly, C., Gurung, R., Kamng'ona, R., Sheha, I., Chammudzi, M., Jambo, K., . . . Klein, N. (2022). Circulating microparticles are increased amongst people presenting with HIV and advanced immune suppression in Malawi and correlate closely with arterial stiffness: a nested case control study. doi:10.12688/wellcomeopenres.17044.2

DOI
10.12688/wellcomeopenres.17044.2
Journal article

Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

Knight, S. R., Gupta, R. K., Ho, A., Pius, R., Buchan, I., Carson, G., . . . Harrison, E. M. (2022). Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77(6), 606-615. doi:10.1136/thoraxjnl-2021-217629

DOI
10.1136/thoraxjnl-2021-217629
Journal article

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).

Abouyannis, M., FitzGerald, R., Ngama, M., Mwangudzah, H., Nyambura, Y. K., Ngome, S., . . . Hamaluba, M. (2022). TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults).. Wellcome open research, 7, 90. doi:10.12688/wellcomeopenres.17682.1

DOI
10.12688/wellcomeopenres.17682.1
Journal article

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

DOI
10.12688/wellcomeopenres.17202.3
Preprint

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.

Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (2021). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry.. Wellcome open research, 6, 246. doi:10.12688/wellcomeopenres.17202.2

DOI
10.12688/wellcomeopenres.17202.2
Journal article

2021

The value of open-source clinical science in pandemic response: lessons from ISARIC

The value of open-source clinical science in pandemic response: lessons from ISARIC (2021). LANCET INFECTIOUS DISEASES, 21(12), 1623-1624. doi:10.1016/S1473-3099(21)00565-X

DOI
10.1016/S1473-3099(21)00565-X
Journal article

The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva

Amara, A., Penchala, S. D., Else, L., Hale, C., FitzGerald, R., Walker, L., . . . Khoo, S. (2021). The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206. doi:10.1016/j.jpba.2021.114356

DOI
10.1016/j.jpba.2021.114356
Journal article

Antiviral activity of Molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance

DOI
10.1101/2021.11.23.469695
Preprint

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Khoo, S. H., Fitzgerald, R., Fletcher, T., Ewings, S., Jaki, T., Lyon, R., . . . Griffiths, G. (2021). Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(12), 3286-3295. doi:10.1093/jac/dkab318

DOI
10.1093/jac/dkab318
Journal article

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry

Olagunju, A., Nwogu, J., Eniayewu, O., Atoyebi, S., Amara, A., Kpamor, J., . . . Khoo, S. (n.d.). Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry. Wellcome Open Research, 6, 246. doi:10.12688/wellcomeopenres.17202.1

DOI
10.12688/wellcomeopenres.17202.1
Journal article

An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

DOI
10.1101/2021.09.10.21263376
Preprint

Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project

Heseltine, T., Murray, S., Ortega-Martorell, S., Olier, I., Lip, G. Y. H., & Khoo, S. (2021). Associations of Hepatosteatosis With Cardiovascular Disease in HIV-Positive and HIV-Negative Patients: The Liverpool HIV-Heart Project. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 87(5), 1221-1227. doi:10.1097/QAI.0000000000002721

DOI
10.1097/QAI.0000000000002721
Journal article

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2

DOI
10.1016/S2666-5247(21)00090-2
Journal article

AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Griffiths, G. O., FitzGerald, R., Jaki, T., Corkhill, A., Reynolds, H., Ewings, S., . . . Khoo, S. (2021). AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. TRIALS, 22(1). doi:10.1186/s13063-021-05458-4

DOI
10.1186/s13063-021-05458-4
Journal article

Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/

Journal article

Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)

Herrera, C., Lwanga, J., Lee, M., Mantori, S., Amara, A., Else, L., . . . Fox, J. (2021). Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2129-2136. doi:10.1093/jac/dkab136

DOI
10.1093/jac/dkab136
Journal article

Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2

DOI
10.1016/S2213-2600(21)00175-2
Journal article

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.

Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1

DOI
10.1016/s2665-9913(21)00104-1
Journal article

Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort

Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178

DOI
10.1002/oby.23178
Journal article

Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8

DOI
10.1016/S2213-2600(21)00013-8
Journal article

Available Agents: Contraindications and Potential Drug–Drug Interactions

Khoo, S., Marra, F., & Boyle, A. (2021). Available Agents: Contraindications and Potential Drug–Drug Interactions. In Hepatitis C: Care and Treatment (pp. 43-74). Springer International Publishing. doi:10.1007/978-3-030-67762-6_4

DOI
10.1007/978-3-030-67762-6_4
Chapter

Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue

Herrera, C., Else, L., Penchala, S. D., Pillay, A. -D. A., Seiphetlo, T. B., Lebina, L., . . . Khoo, S. (2021). Pharmacokinetic and pharmacodynamic study of tenofovir and tenofovir alafenamide for PrEP in foreskin tissue. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 24. Retrieved from https://www.webofscience.com/

Conference Paper

2020

Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020

Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685

DOI
10.2807/1560-7917.ES.2020.25.42.2000685
Journal article

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

Stader, F., Khoo, S., Stoeckle, M., Back, D., Hirsch, H. H., Battegay, M., & Marzolini, C. (2020). Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(10), 3084-3086. doi:10.1093/jac/dkaa253

DOI
10.1093/jac/dkaa253
Journal article

Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study

Lopez-Centeno, B., Badenes-Olmedo, C., Mataix-Sanjuan, A., McAllister, K., Bellon, J. M., Gibbons, S., . . . Berenguer, J. (2020). Polypharmacy and Drug-Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. In CLINICAL INFECTIOUS DISEASES Vol. 71 (pp. 353-362). doi:10.1093/cid/ciz811

DOI
10.1093/cid/ciz811
Conference Paper

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy

Pushpakom, S. P., Kolamunnage-Dona, R., Taylor, C., Foster, T., Spowart, C., Garcia-Finana, M., . . . Pirmohamed, M. (n.d.). TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases. doi:10.1093/cid/ciz589

DOI
10.1093/cid/ciz589
Journal article

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment

Francis, J., Barnes, K. I., Workman, L., Kredo, T., Vestergaard, L. S., Hoglund, R. M., . . . Denti, P. (2020). An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(5). doi:10.1128/AAC.02394-19

DOI
10.1128/AAC.02394-19
Journal article

Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)

Tiraboschi, J., Imaz, A., Khoo, S., Niubo, J., Prieto, P., Saumoy, M., . . . Podzamczer, D. (2020). Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56). JOURNAL OF INFECTIOUS DISEASES, 221(9), 1425-1428. doi:10.1093/infdis/jiz624

DOI
10.1093/infdis/jiz624
Journal article

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G&gt;T Genotypes

Abdullahi, S. T., Soyinka, J. O., Olagunju, A., Bolarinwa, R. A., Olarewaju, O. J., Bakare-Odunola, M. T., . . . Khoo, S. (2020). Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G&gt;T Genotypes. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(3). doi:10.1128/AAC.00947-19

DOI
10.1128/AAC.00947-19
Journal article

Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial

Arenas-Pinto, A., Stohr, W., Khoo, S., Clarke, A., Beeching, N., Warwick, Z., . . . Paton, N. I. (2020). Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial. ANTIVIRAL THERAPY, 25(1), 55-59. doi:10.3851/IMP3340

DOI
10.3851/IMP3340
Journal article

TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care

McCallum, A. D., Sheha, I., Chasweka, M., Banda, G., Davies, G. R., Khoo, S. H., . . . Sloan, D. J. (2020). TB control programmes remain an important gateway to HIV diagnosis in the era of expanded access to HIV care. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 24(1), 131-132. doi:10.5588/ijtld.19.0504

DOI
10.5588/ijtld.19.0504
Journal article

The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid

Penchala, S. D., Alagaratnam, J., Challenger, E., Amara, A., Else, L., Winston, A., & Khoo, S. (2020). The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. BIOMEDICAL CHROMATOGRAPHY, 34(1). doi:10.1002/bmc.4711

DOI
10.1002/bmc.4711
Journal article

2019

Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

Penazzato, M., Townsend, C. L., Rakhmanina, N., Cheng, Y., Archary, M., Cressey, T. R., . . . Townsend, C. (2019). Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. LANCET HIV, 6(9), E623-E631. doi:10.1016/S2352-3018(19)30193-6

DOI
10.1016/S2352-3018(19)30193-6
Journal article

Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial

Banda, C. G., Chaponda, M., Mukaka, M., Mulenga, M., Hachizovu, S., Kabuya, J. B., . . . Mwapasa, V. (2019). Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial. MALARIA JOURNAL, 18. doi:10.1186/s12936-019-2818-7

DOI
10.1186/s12936-019-2818-7
Journal article

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment

Alagaratnam, J., Dilly-Penchala, S., Challenger, E., Else, L., Legg, K., Petersen, C., . . . Winston, A. (2019). Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 85 (pp. 1039-1040). doi:10.1111/bcp.13878

DOI
10.1111/bcp.13878
Conference Paper

HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8+ T Cells and Reverses With Antiretroviral Therapy

Kelly, C., Mwandumba, H. C., Heyderman, R. S., Jambo, K., Kamng'ona, R., Chammudzi, M., . . . Khoo, S. (2019). HIV-Related Arterial Stiffness in Malawian Adults Is Associated With the Proportion of PD-1–Expressing CD8+ T Cells and Reverses With Antiretroviral Therapy. The Journal of infectious diseases. doi:10.1093/infdis/jiz015

DOI
10.1093/infdis/jiz015
Journal article

Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website

Gibbons, S., Marzolini, C., Moss, C., McAllister, K., Chiong, J., Back, D., & Khoo, S. (2019). Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website. In HIV MEDICINE Vol. 20 (pp. 44-45). Retrieved from https://www.webofscience.com/

Conference Paper

The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial

Fox, J., Herrera, C., Lwanga, J., Lee, M., Else, L., Amara, A., . . . Dickenson, L. (2019). The role of raltegravir alone or combined with lamivudine as PrEP: a phase 2 randomised controlled clinical trial. In HIV MEDICINE Vol. 20 (pp. 5-6). Retrieved from https://www.webofscience.com/

Conference Paper

2018

Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk

Gini, J., Penchala, S. D., Amara, A., Challenger, E., Egan, D., Waitt, C., . . . Else, L. J. (2018). Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. BIOANALYSIS, 10(23), 1933-1945. doi:10.4155/bio-2018-0085

DOI
10.4155/bio-2018-0085
Journal article

Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.

Gini, J., Amara, A., Penchala, S. D., Back, D. J., Else, L., Egan, D., . . . Khoo, S. H. (2018). Widespread use of herbal medicines by people living with human immunodeficiency virus and contamination of herbal medicines with antiretrovirals in Nigeria.. International journal of STD & AIDS, 956462418809749. doi:10.1177/0956462418809749

DOI
10.1177/0956462418809749
Journal article

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in <i>Plasmodium falciparum</i>-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy

Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in <i>Plasmodium falciparum</i>-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(11). doi:10.1128/AAC.01162-18

DOI
10.1128/AAC.01162-18
Journal article

Novel online drug-drug interaction resource reveals clinically relevant interactions in &gt;20% of the searches

Lankheet, N. A. G., Ferrier, K. R. M., Gibbons, S. E., Burger, D. M., McAllister, K., Martin, J. L. M., . . . Jansman, F. G. (2018). Novel online drug-drug interaction resource reveals clinically relevant interactions in &gt;20% of the searches. In ANNALS OF ONCOLOGY Vol. 29. Retrieved from https://www.webofscience.com/

Conference Paper

Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters

Danjuma, M. I., Egan, D., Abubeker, I. Y., Post, F., & Khoo, S. (2018). Polymorphisms of tenofovir disoproxil fumarate transporters and risk of kidney tubular dysfunction in HIV-positive patients: genetics of tenofovir transporters. INTERNATIONAL JOURNAL OF STD & AIDS, 29(14), 1384-1389. doi:10.1177/0956462418786562

DOI
10.1177/0956462418786562
Journal article

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

Imaz, A., Niubo, J., Amara, A., Khoo, S., Ferrer, E., Tiraboschi, J. M., . . . Podzamczer, D. (2018). Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39). JOURNAL OF NEUROVIROLOGY, 24(4), 391-397. doi:10.1007/s13365-018-0626-4

DOI
10.1007/s13365-018-0626-4
Journal article

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(8). doi:10.1128/AAC.00634-18

DOI
10.1128/AAC.00634-18
Journal article

Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.

Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics of Piperaquine and Safety Profile of Dihydroartemisinin-Piperaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.. Antimicrobial agents and chemotherapy, 62(8), e00634-e00618. doi:10.1128/aac.00634-18

DOI
10.1128/aac.00634-18
Journal article

DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy

Orrell, C., Kintu, K., Coombs, J. A., Amara, A., Myer, L., Kaboggoza, J., . . . Lamorde, M. (2018). DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21 (pp. 166). Retrieved from https://www.webofscience.com/

Conference Paper

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

Stader, F., Kinvig, H., Battegay, M., Khoo, S., Owen, A., Siccardi, M., & Marzolini, C. (2018). Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00717-18

DOI
10.1128/AAC.00717-18
Journal article

Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults

Banda, C. G., Dzinjalamala, F., Mukaka, M., Mallewa, J., Maiden, V., Terlouw, D. J., . . . Mwapasa, V. (2018). Pharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(7). doi:10.1128/AAC.00412-18

DOI
10.1128/AAC.00412-18
Journal article

Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

Walimbwa, S., Lamorde, M., Waitt, C., Kaboggoza, J., Else, L., Byakika-Kibwika, P., . . . Khoo, S. (2018). Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. doi:10.1101/351684

DOI
10.1101/351684
Journal article

Development of an online drug-drug interaction resource to support prescribing of oncolytics

Lankheet, N. A. G., Jansman, F. G., Gibbons, S. E., Burger, D. M., McAllister, K., Khoo, S. H., & Van Erp, N. P. (2017). Development of an online drug-drug interaction resource to support prescribing of oncolytics. In ANNALS OF ONCOLOGY Vol. 28. Retrieved from https://www.webofscience.com/

Conference Paper

Development of an online drug-drug interaction resource to support safe prescription of oncolytics.

Van Erp, N. P., Ferrier, K. R. M., Gibbons, S. E., Burger, D., McAllister, K., Martin, J. L. M., . . . Lankheet, N. A. G. (2018). Development of an online drug-drug interaction resource to support safe prescription of oncolytics.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.e18574

DOI
10.1200/JCO.2018.36.15_suppl.e18574
Conference Paper

Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals

Mora-Peris, B., Bouliotis, G., Ranjababu, K., Clarke, A., Post, F. A., Nelson, M., . . . Winston, A. (2018). Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. AIDS, 32(8), 1007-1015. doi:10.1097/QAD.0000000000001786

DOI
10.1097/QAD.0000000000001786
Journal article

Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

Marra, F., zu Siederdissen, C. H., Khoo, S., Back, D., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Cornberg, M. (2018). Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 84(5), 961-971. doi:10.1111/bcp.13519

DOI
10.1111/bcp.13519
Journal article

Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma

Cirrincione, L. R., Penchala, S. D., Scarsi, K. K., Podany, A. T., Winchester, L. C., Back, D. J., . . . Else, L. J. (2018). Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1084, 106-112. doi:10.1016/j.jchromb.2018.03.023

DOI
10.1016/j.jchromb.2018.03.023
Journal article

Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs

Waitt, C., Olagunju, A., Nakalema, S., Kyohaire, I., Owen, A., Lamorde, M., & Khoo, S. (2018). Plasma and Breast Milk Pharmacokinetics of Emtricitabine, Tenofovir and Lamivudine Using Dried Blood and Breast Milk Spots in Nursing African Mother-Infant Pairs. Journal of Antimicrobial Chemotherapy, 73(4), 1013-1019. doi:10.1093/jac/dkx507

DOI
10.1093/jac/dkx507
Journal article

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals

Jackson, A., Else, L., Higgs, C., Karolia, Z., Khoo, S., Back, D., . . . Boffito, M. (2018). Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naive HIV-1-infected individuals. HIV CLINICAL TRIALS, 19(1), 31-37. doi:10.1080/15284336.2017.1408928

DOI
10.1080/15284336.2017.1408928
Journal article

Development of a drug-drug interaction website to support prescribing of oncolytics

Ferrier, K., Jansman, F., Burger, D., McAllister, K., Gibbons, S., Khoo, S., . . . Lankheet, N. (2018). Development of a drug-drug interaction website to support prescribing of oncolytics. In INTERNATIONAL JOURNAL OF CLINICAL PHARMACY Vol. 40 (pp. 735-736). Retrieved from https://www.webofscience.com/

Conference Paper

HIV infection and stroke.

Benjamin, L., & Khoo, S. (2018). HIV infection and stroke.. Handbook of clinical neurology, 152, 187-200. doi:10.1016/b978-0-444-63849-6.00015-3

DOI
10.1016/b978-0-444-63849-6.00015-3
Journal article

Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT

Nash, S., Herrera, C., Serwanga, J., Ruzagira, E., O'Hagan, K., Kelly, C., . . . Fox, J. (2018). Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT. In AIDS RESEARCH AND HUMAN RETROVIRUSES Vol. 34 (pp. 364). Retrieved from https://www.webofscience.com/

Conference Paper

Plasma NRTI concentrations and renal function in people with HIV

Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI concentrations and renal function in people with HIV. In HIV MEDICINE Vol. 19 (pp. S16-S17). Retrieved from https://www.webofscience.com/

Conference Paper

Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV

Wang, X., Boffito, M., Dickinson, L., Bagkeris, E., Khoo, S., Post, F., . . . Sabin, C. (2018). Plasma NRTI exposure and associations with serum alanine aminotransferase in people living with HIV. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/

Conference Paper

Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort

Okoli, C., Khoo, S., Schwenk, A., Radford, M., Myland, M., Taylor, S., . . . Benn, P. (2018). Using Climate-HIV to describe non-antiretroviral use and potential DDIs for people living with HIV within a UK cohort. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 21. Retrieved from https://www.webofscience.com/

Conference Paper

2017

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. Retrieved from http://gateway.webofknowledge.com/

Journal article

Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.

El-Sherif, O., Pertinez, H., Irving, W., Penchala, S. D., McLauchlan, J., Foster, G. R., . . . Khoo, S. (2017). Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme.. In HEPATOLOGY Vol. 66 (pp. 831A-832A). Retrieved from https://www.webofscience.com/

Conference Paper

Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS

Waitt, C., Penchala, S. D., Olagunju, A., Amara, A., Else, L., Lamorde, M., & Khoo, S. (2017). Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS. Journal of Chromatography B, 1060, 300-307. doi:10.1016/j.jchromb.2017.06.012

DOI
10.1016/j.jchromb.2017.06.012
Journal article

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge

Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2035-2041. doi:10.1093/jac/dkx108

DOI
10.1093/jac/dkx108
Journal article

Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017)

Elliot, E. R., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2017). Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge (vol 72, pg 2035, 2017). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(7), 2143. doi:10.1093/jac/dkx145

DOI
10.1093/jac/dkx145
Journal article

Genome-Wide Association Study of Nevirapine Hypersensitivity in a sub-Saharan African HIV-infected Population

Carr, D. F., Bourgeois, S., Chaponda, M., Takeshita, L., Morris, A., Cornejo Castro, E. M., . . . Pirmohamed, M. (2017). Genome-Wide Association Study of Nevirapine Hypersensitivity in a sub-Saharan African HIV-infected Population. Journal of Antimicrobial Chemotherapy, 72(4), 1152-1162. doi:10.1093/jac/dkw545

DOI
10.1093/jac/dkw545
Journal article

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection

Seden, K., Gibbons, S., Marzolini, C., Schapiro, J. M., Burger, D. M., Back, D. J., & Khoo, S. H. (2017). Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173509

DOI
10.1371/journal.pone.0173509
Journal article

ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.

Bracchi, M., Neary, M. G., Pagani, N., Else, L., Khoo, S., Abbas, Z., . . . Boffito, M. (n.d.). ABCG2 rs2231142 influences tenofovir concentrations in plasma and urine.. In CROI. Seattle, WA, USA.

Conference Paper

An open-label multiple-dose phase 1 assessment of long-acting rilpivirine

McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Shetler, C., Richardson-Harman, N., . . . Cranston, R. D. (2017). An open-label multiple-dose phase 1 assessment of long-acting rilpivirine. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 20 (pp. 31). Retrieved from https://www.webofscience.com/

Conference Paper

Case report: atazanavir associated cholelithiasis

Howlett, P., Simons, R., Wilkinson, M., Kulasegaram, R., Elsie, L., & Khoo, S. (2017). Case report: atazanavir associated cholelithiasis. In HIV MEDICINE Vol. 18 (pp. 15). Retrieved from https://www.webofscience.com/

Conference Paper

Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study

Amara, A. B., Else, L. J., Carey, D., Khoo, S., Back, D. J., Amin, J., . . . Puls, R. L. (2017). Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study. THERAPEUTIC DRUG MONITORING, 39(6), 654-658. doi:10.1097/FTD.0000000000000448

DOI
10.1097/FTD.0000000000000448
Journal article

Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies

Marra, F., Siederdissen, C. H. Z., Khoo, S., Cornberg, M., Schlag, M., Ouwerkerk-Mahadevan, S., . . . Back, D. (2017). Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies. In JOURNAL OF HEPATOLOGY Vol. 66 (pp. S314). Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women

Khoo, S., Peytavin, G., Burger, D., Hill, A., Brown, K., Moecklinghoff, C., . . . Hadacek, M. B. (2017). Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women. AIDS REVIEWS, 19(1), 16-23. Retrieved from https://www.webofscience.com/

Journal article

2016

Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia

Nightingale, S., Geretti, A. M., Beloukas, A., Fisher, M., Winston, A., Else, L., . . . Khoo, S. (2016). Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia. Journal of NeuroVirology, 22, 852-860. doi:10.1007/s13365-016-0448-1

DOI
10.1007/s13365-016-0448-1
Journal article

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

McGowan, I., Dezzutti, C. S., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., . . . Cranston, R. D. (2016). Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. LANCET HIV, 3(12), E569-E578. doi:10.1016/S2352-3018(16)30113-8

DOI
10.1016/S2352-3018(16)30113-8
Journal article

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.

Fox, J., Tiraboschi, J. M., Herrera, C., Else, L., Egan, D., Dickinson, L., . . . Boffito, M. (2016). Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.. Journal of acquired immune deficiency syndromes (1999), 73(3), 252-257. doi:10.1097/qai.0000000000001108

DOI
10.1097/qai.0000000000001108
Journal article

Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice

Elliot, E., Amara, A., Pagani, N., Else, L., Moyle, G., Schoolmeesters, A., . . . Boffito, M. (2016). Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/

Conference Paper

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

Churchill, D., Waters, L., Ahmed, N., Angus, B., Boffito, M., Bower, M., . . . Winston, A. (2016). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV MEDICINE, 17, S2-S104. doi:10.1111/hiv.12426

DOI
10.1111/hiv.12426
Journal article

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis

Nightingale, S., Chau, T. T. H., Fisher, M., Nelson, M., Winston, A., Else, L., . . . Grp, P. -V. S. (2016). Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G -> T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis. Antimicrobial Agents and Chemotherapy, 60(8), 4511-4518. doi:10.1128/AAC.00280-16

DOI
10.1128/AAC.00280-16
Journal article

Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study

Olagunju, A., Bolaji, O., Neary, M., Back, D., Khoo, S., & Owen, A. (2016). Pregnancy affects nevirapine pharmacokinetics: evidence from a <i>CYP2B6</i> genotype-guided observational study. PHARMACOGENETICS AND GENOMICS, 26(8), 381-389. doi:10.1097/FPC.0000000000000227

DOI
10.1097/FPC.0000000000000227
Journal article

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma

Penchala, S. D., Fawcett, S., Else, L., Egan, D., Amara, A., Elliot, E., . . . Khoo, S. (2016). The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 1027, 174-180. doi:10.1016/j.jchromb.2016.05.040

DOI
10.1016/j.jchromb.2016.05.040
Journal article

CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF

Nightingale, S., Michael, B. D., Fisher, M., Winston, A., Nelson, M., Taylor, S., . . . Solomon, T. (2016). CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. Cytokine, 83, 139-146. doi:10.1016/j.cyto.2016.04.004

DOI
10.1016/j.cyto.2016.04.004
Journal article

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications

Marzolini, C., Gibbons, S., Khoo, S., & Back, D. (2016). Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(7), 1755-1758. doi:10.1093/jac/dkw032

DOI
10.1093/jac/dkw032
Journal article

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2016). Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naive HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study. CLINICAL PHARMACOKINETICS, 55(7), 861-873. doi:10.1007/s40262-015-0360-5

DOI
10.1007/s40262-015-0360-5
Journal article

Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis

Olagunju, A., Khoo, S., & Owen, A. (2016). Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis. PHARMACOGENOMICS, 17(8), 891-906. doi:10.2217/pgs-2015-0016

DOI
10.2217/pgs-2015-0016
Journal article

Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake

Elliot, E., Amara, A., Jackson, A., Moyle, G., Else, L., Khoo, S., . . . Boffito, M. (2016). Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1031-1036. doi:10.1093/jac/dkv425

DOI
10.1093/jac/dkv425
Journal article

Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.

Gathogo, E., Harber, M., Bhagani, S., Levy, J., Jones, R., Hilton, R., . . . UK HIV Kidney Transplantation Study Group. (2016). Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.. Transplantation, 100(4), 871-878. doi:10.1097/tp.0000000000000879

DOI
10.1097/tp.0000000000000879
Journal article

Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease

Molto, J., Graterol, F., Miranda, C., Khoo, S., Bancu, I., Amara, A., . . . Clotet, B. (2016). Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(4), 2564-2566. doi:10.1128/AAC.03131-15

DOI
10.1128/AAC.03131-15
Journal article

Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 71(4), 1041-1045. doi:10.1093/jac/dkv439

DOI
10.1093/jac/dkv439
Journal article

Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports

Fox, J., Brady, M., Alexander, H., Davies, O., Robinson, N., Pace, M., . . . Frater, J. (2016). Tenofovir Disoproxil Fumarate Fails to Prevent HIV Acquisition or the Establishment of a Viral Reservoir: Two Case Reports. INFECTIOUS DISEASES AND THERAPY, 5(1), 65-71. doi:10.1007/s40121-015-0102-x

DOI
10.1007/s40121-015-0102-x
Journal article

Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro

Roberts, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016). Interaction of Darunavir/Ritonavir and Darunavir/Cobicistat With Rifampicin In Vitro. In CROI. Boston, USA.

Conference Paper

Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Vitoria, M., Hill, A. M., Ford, N. P., Doherty, M., Khoo, S. H., & Pozniak, A. L. (2016). Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 19. doi:10.7448/IAS.19.1.20504

DOI
10.7448/IAS.19.1.20504
Journal article

Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort

Lewis, J. M., Stott, K. E., Monnery, D., Seden, K., Beeching, N. J., Chaponda, M., . . . Beadsworth, M. B. J. (2016). Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. INTERNATIONAL JOURNAL OF STD & AIDS, 27(2), 105-109. doi:10.1177/0956462415574632

DOI
10.1177/0956462415574632
Journal article

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial

McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., . . . Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53-60. doi:10.1016/S0140-6736(15)00056-2

DOI
10.1016/S0140-6736(15)00056-2
Journal article

A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol

Quinn, K., Bouliotis, G., Doyle, N., Winston, A., Ashby, D., Weber, J., . . . Pessi, A. (2016). A first-in-human study, in HIV-positive men, of the novel HIV-fusion inhibitor C34-PEG4-Chol. HIV MEDICINE, 17, 18. Retrieved from https://www.webofscience.com/

Journal article

DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION

El-Sherif, O., Stewart, S., Bergin, C., McKiernan, S., Crosbie, O., Khoo, S., & Norris, S. (2016). DETERMINATION OF LEDIPASVIR CONCENTRATIONS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS RECEIVING LOW DOSE PROTON PUMP INHIBITORS DURING SOFOSBUVIR-LEDIPASVIR TREATMENT FOR HCV GENOTYPE 1 INFECTION. In JOURNAL OF HEPATOLOGY Vol. 64 (pp. S805-S806). doi:10.1016/S0168-8278(16)01573-7

DOI
10.1016/S0168-8278(16)01573-7
Conference Paper

Persistence of rilpivirine following single dose of long-acting injection

McGowan, I., Siegel, A., Engstrom, J., Nikiforov, A., Duffill, K., Edick, S., . . . Cranston, R. D. (2016). Persistence of rilpivirine following single dose of long-acting injection. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY Vol. 19. Retrieved from https://www.webofscience.com/

Conference Paper

Single dose Maraviroc provides high drug levels in all sites; no gender differences

Tiraboschi, J., Davies, O., Fox, J., Else, L., Egan, D., Amara, A., . . . Boffito, M. (2016). Single dose Maraviroc provides high drug levels in all sites; no gender differences. HIV MEDICINE, 17, 17. Retrieved from https://www.webofscience.com/

Journal article

2015

Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults

Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3298-3306. doi:10.1093/jac/dkv268

DOI
10.1093/jac/dkv268
Journal article

Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

Seden, K., Merry, C., Hewson, R., Siccardi, M., Lamorde, M., Byakika-Kibwika, P., . . . Khoo, S. H. (2015). Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(12), 3317-3322. doi:10.1093/jac/dkv259

DOI
10.1093/jac/dkv259
Journal article

Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers

Seng, K. -Y., Hee, K. -H., Soon, G. -H., Chew, N., Khoo, S. H., & Lee, L. S. -U. (2015). Population Pharmacokinetic Analysis of Isoniazid, Acetylisoniazid, and Isonicotinic Acid in Healthy Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(11), 6791-6799. doi:10.1128/AAC.01244-15

DOI
10.1128/AAC.01244-15
Journal article

Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIVpositive individuals on combination antiretroviral therapy

Pushpakom, S., Taylor, C., Kolamunnage-Dona, R., Spowart, C., Vora, J., Garcia Finana, M., . . . Pirmohamed, M. (2015). Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIVpositive individuals on combination antiretroviral therapy. BMJ Open, 5(10). doi:10.1136/bmjopen-2015-009566

DOI
10.1136/bmjopen-2015-009566
Journal article

Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation

Dickinson, L., Yapa, H. M., Jackson, A., Moyle, G., Else, L., Amara, A., . . . Boffito, M. (2015). Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 59(10), 6080-6086. doi:10.1128/AAC.01441-15

DOI
10.1128/AAC.01441-15
Journal article

Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots

Olagunju, A., Amara, A., Waitt, C., Else, L., Penchala, S. D., Bolaji, O., . . . Khoo, S. (2015). Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2816-2822. doi:10.1093/jac/dkv174

DOI
10.1093/jac/dkv174
Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . Puls, R. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.. Clinical pharmacology and therapeutics, 98(4), 406-416. doi:10.1002/cpt.156

DOI
10.1002/cpt.156
Journal article

Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection

El-Sherif, O., Khoo, S., & Solas, C. (2015). Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection. CURRENT OPINION IN HIV AND AIDS, 10(5), 348-354. doi:10.1097/COH.0000000000000185

DOI
10.1097/COH.0000000000000185
Journal article

Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety

Bracchi, M., Stuart, D., Castles, R., Khoo, S., Back, D., & Boffito, M. (2015). Increasing use of 'party drugs' in people living with HIV on antiretrovirals: a concern for patient safety. AIDS, 29(13), 1585-1592. doi:10.1097/QAD.0000000000000786

DOI
10.1097/QAD.0000000000000786
Journal article

Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Olagunju, A., Bolaji, O., Amara, A., Waitt, C., Else, L., Adejuyigbe, E., . . . Owen, A. (2015). Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study. Clin Infect Dis, 61(3), 453-463. doi:10.1093/cid/civ317

DOI
10.1093/cid/civ317
Journal article

Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes

Sloan, D. J., Mwandumba, H. C., Kamdolozi, M., Shani, D., Chisale, B., Dutton, J., . . . Davies, G. R. (2015). Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 19(8), 904-911. doi:10.5588/ijtld.15.0071

DOI
10.5588/ijtld.15.0071
Journal article

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis

Cummins, N. W., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J. K., . . . Badley, A. D. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBIOMEDICINE, 2(7), 706-712. doi:10.1016/j.ebiom.2015.05.012

DOI
10.1016/j.ebiom.2015.05.012
Journal article

Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies

Waitt, C. J., Garner, P., Bonnett, L. J., Khoo, S. H., & Else, L. J. (2015). Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(7), 1928-1941. doi:10.1093/jac/dkv080

DOI
10.1093/jac/dkv080
Journal article

Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis

Sloan, D. J., Mwandumba, H. C., Garton, N. J., Khoo, S. H., Butterworth, A. E., Allain, T. J., . . . Davies, G. R. (2015). Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clinical Infectious Diseases, 61(1), 1-8. doi:10.1093/cid/civ195

DOI
10.1093/cid/civ195
Journal article

Second European Round Table on the Future Management of HIV 10-11 October 2014, Barcelona, Spain

Rokx, C., Richman, D. D., Muller-Trutwin, M., Silvestri, G., van Lunzen, J., Khoo, S., . . . Boucher, C. A. B. (2015). Second European Round Table on the Future Management of HIV 10-11 October 2014, Barcelona, Spain. JOURNAL OF VIRUS ERADICATION, 1(3), 211-220. Retrieved from https://www.webofscience.com/

Journal article

Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study

Dickinson, L., Amin, J., Else, L., Boffito, M., Egan, D., Owen, A., . . . R Puls, O. B. O. T. E. S. G. (2015). Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. Clin Pharmacol Ther, 98(4), 406-416.

Journal article

A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers

Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Cooke, G., . . . Winston, A. (2015). A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(6), 1812-1815. doi:10.1093/jac/dkv035

DOI
10.1093/jac/dkv035
Journal article

Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus

van de Ven, N., Fortunak, J., Simmons, B., Ford, N., Cooke, G. S., Khoo, S., & Hill, A. (2015). Minimum Target Prices for Production of Direct-Acting Antivirals and Associated Diagnostics to Combat Hepatitis C Virus. HEPATOLOGY, 61(4), 1174-1182. doi:10.1002/hep.27641

DOI
10.1002/hep.27641
Journal article

Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics

Olagunju, A., Bolaji, O., Amara, A., Else, L., Okafor, O., Adejuyigbe, E., . . . Owen, A. (2015). Pharmacogenetics of Pregnancy-Induced Changes in Efavirenz Pharmacokinetics. CLINICAL PHARMACOLOGY & THERAPEUTICS, 97(3), 298-306. doi:10.1002/cpt.43

DOI
10.1002/cpt.43
Journal article

A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS

Mora-Peris, B., Else, L., Goldmeier, D., Mears, A., Weston, R., Graham, C., . . . Winston, A. (2015). A PHASE 1 STUDY TO ASSESS THE SAFETY, TOLERABILITY AND PHARMACOKINETIC PROFILE OF BOCEPREVIR AND SILDENAFIL WHEN DOSED SEPARATELY AND TOGETHER, IN HEALTHY MALE VOLUNTEERS. SEXUALLY TRANSMITTED INFECTIONS, 91, A78. doi:10.1136/sextrans-2015-052126.231

DOI
10.1136/sextrans-2015-052126.231
Journal article

Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS

Olagunju, A., Bolaji, O. O., Amara, A., Waitt, C., Else, L., Soyinka, J., . . . Khoo, S. (2015). Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 555-561. doi:10.1093/jac/dku420

DOI
10.1093/jac/dku420
Journal article

Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir

Reynolds, H. E., Chrdle, A., Egan, D., Chaponda, M., Else, L., Chiong, J., . . . Khoo, S. H. (2015). Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(2), 550-554. doi:10.1093/jac/dku376

DOI
10.1093/jac/dku376
Journal article

A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1

Tiraboschi, J., Fox, J., Herrera, C., Olejniczak, N., Jackson, A., Boffito, M., . . . Shattock, R. (2015). A Phase IV HIV PrEP study reveals limited ex vivo potency of oral Maraviroc against HIV-1. HIV MEDICINE, 16, 3-4. Retrieved from https://www.webofscience.com/

Journal article

CSF:plasma HIV-1 RNA discordance &gt;0.5 log<sub>10</sub> is associated with raised inflammatory mediator profiles in CSF

Nightingale, S., Michael, B., King, S., Beloukas, A., Pirmohamed, M., Geretti, A. M., . . . Post, F. (2015). CSF:plasma HIV-1 RNA discordance &gt;0.5 log<sub>10</sub> is associated with raised inflammatory mediator profiles in CSF. HIV MEDICINE, 16, 7. Retrieved from https://www.webofscience.com/

Journal article

Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies

El-Sherif, O., Houlihan, D. D., Stewart, S., Bergin, C. J., Fanning, L. J., McKiernan, S., . . . Khoo, S. H. (2015). Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies. In HEPATOLOGY Vol. 62 (pp. 752A). Retrieved from https://www.webofscience.com/

Conference Paper

Developing a new virtual HIV network: Our region's experience

Wolujewicz, A., Lewis, J., Chaponda, M., Chiong, J., & Khoo, S. (2015). Developing a new virtual HIV network: Our region's experience. HIV MEDICINE, 16, 69-70. Retrieved from https://www.webofscience.com/

Journal article

Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations

El-Sherif, O., Dilly, P. S., Else, L., McKiernan, S., Khoo, S., & Norris, S. (2015). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy: need for "real world" PK studies to identify vulnerable populations. IRISH JOURNAL OF MEDICAL SCIENCE, 184, S218. Retrieved from https://www.webofscience.com/

Journal article

Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults

Lamorde, M., Walimbwa, S., Byakika-Kibwika, P., Katwere, M., Mukisa, L., Sempa, J. B., . . . Merry, C. (2015). Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults. J Antimicrob Chemother, 70(5), 1482-1486.

Journal article

Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine

Schipani, A., Back, D., Owen, A., Davies, G., Khoo, S., & Siccardi, M. (2015). Use of In Vitro to In Vivo Extrapolation to Predict the Optimal Strategy for Patients Switching from Efavirenz to Maraviroc or Nevirapine. CLINICAL PHARMACOKINETICS, 54(1), 107-116. doi:10.1007/s40262-014-0184-8

DOI
10.1007/s40262-014-0184-8
Journal article

2014

Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi

Aoudjane, S., Chaponda, M., Gonzalez Del Castillo, A. A., O'Connor, J., Noguera, M., Beloukas, A., . . . Geretti, A. M. (2014). Hepatitis B Virus Sub-genotype A1 Infection Is Characterized by High Replication Levels and Rapid Emergence of Drug Resistance in HIV-Positive Adults Receiving First-line Antiretroviral Therapy in Malawi. Clinical Infectious Diseases, 59(11), 1618-1626. doi:10.1093/cid/ciu630

DOI
10.1093/cid/ciu630
Journal article

RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS

Sloan, D. J., Guwende, C., Banda, G., Shani, D., Kamdolozi, M., Chisale, B., . . . Davies, G. R. (2014). RISK FACTORS AND THERAPEUTIC IMPLICATIONS OF VITAMIN D DEFICIENCY IN MALAWIAN ADULTS WITH PULMONARY TUBERCULOSIS. In THORAX Vol. 69 (pp. A42). doi:10.1136/thoraxjnl-2014-206260.81

DOI
10.1136/thoraxjnl-2014-206260.81
Conference Paper

A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops

Lewis, J., Turtle, L., Khoo, S., & Nsutebu, E. (2014). A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS, 28(17), 2636-2637. doi:10.1097/QAD.0000000000000462

DOI
10.1097/QAD.0000000000000462
Journal article

Darunavir pharmacokinetics throughout pregnancy and postpartum

Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. J Int AIDS Soc, 17(4 Supp), 19485.

Journal article

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int AIDS Soc, 17(4 Supp), 19484.

Journal article

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV‐infected patients: a population PK approach. Journal of the International AIDS Society, 17(4S3). doi:10.7448/ias.17.4.19586

DOI
10.7448/ias.17.4.19586
Journal article

Controversies in HIV-associated neurocognitive disorders

Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014). Controversies in HIV-associated neurocognitive disorders. LANCET NEUROLOGY, 13(11), 1139-1151. doi:10.1016/S1474-4422(14)70137-1

DOI
10.1016/S1474-4422(14)70137-1
Journal article

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

Scarsi, K., Lamorde, M., Darin, K., Penchala, S. D., Else, L., Nakalema, S., . . . Back, D. (2014). Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 4. doi:10.7448/IAS.17.4.19484

DOI
10.7448/IAS.17.4.19484
Journal article

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy

Else, L. J., Jackson, V., Brennan, M., Back, D. J., Khoo, S. H., Coulter-Smith, S., & Lambert, J. S. (2014). Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. HIV MEDICINE, 15(10), 604-610. doi:10.1111/hiv.12164

DOI
10.1111/hiv.12164
Journal article

No pharmacokinetic interaction between raltegravir and amlodipine

Singh, G. J., Jackson, A., D’Avolio, A., Else, L., De Nicolò, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine. AIDS, 28(13), 1993-1995. doi:10.1097/qad.0000000000000356

DOI
10.1097/qad.0000000000000356
Journal article

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals

Singh, G. J., Jackson, A., D'Avolio, A., Else, L., De Nicolo, A., Bonora, S., . . . Boffito, M. (2014). No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. AIDS, 28(13), 1993-1995. doi:10.1097/QAD.0000000000000356

DOI
10.1097/QAD.0000000000000356
Journal article

HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study

Kelly, C. M., van Oosterhout, J. J., Ngwalo, C., Stewart, R. C., Benjamin, L., Robertson, K. R., . . . Solomon, T. (2014). HIV Associated Neurocognitive Disorders (HAND) in Malawian Adults and Effect on Adherence to Combination Anti-Retroviral Therapy: A Cross Sectional Study. PLOS ONE, 9(6). doi:10.1371/journal.pone.0098962

DOI
10.1371/journal.pone.0098962
Journal article

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(6), 1642-1647. doi:10.1093/jac/dku018

DOI
10.1093/jac/dku018
Journal article

Abacavir forms novel cross-linking abacavir protein adducts in patients

Meng, X., Lawrenson, A. S., Berry, N. G., Maggs, J. L., French, N. S., Back, D. J., . . . Park, B. K. (2014). Abacavir forms novel cross-linking abacavir protein adducts in patients. Chemical Research in Toxicology, 27(04), 524-535. doi:10.1021/tx400406p

DOI
10.1021/tx400406p
Journal article

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries

Hill, A., Khoo, S., Fortunak, J., Simmons, B., & Ford, N. (2014). Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical Infectious Diseases, 58(7), 928-936. doi:10.1093/cid/ciu012

DOI
10.1093/cid/ciu012
Journal article

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity

Yombi, J. C., Pozniak, A., Boffito, M., Jones, R., Khoo, S., Levy, J., & Post, F. A. (2014). Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity. AIDS, 28(5), 621-632. doi:10.1097/QAD.0000000000000103

DOI
10.1097/QAD.0000000000000103
Journal article

Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation

McDonald, T. O., Giardiello, M., Martin, P., Siccardi, M., Liptrott, N. J., Roberts, P., . . . Owen, A. (2014). Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Advanced Healthcare Materials, 3(3), 400-411. doi:10.1002/adhm.201300280

DOI
10.1002/adhm.201300280
Journal article

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

Karageorgopoulos, D. E., El-Sherif, O., Bhagani, S., & Khoo, S. H. (2014). Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. CURRENT OPINION IN INFECTIOUS DISEASES, 27(1), 36-45. doi:10.1097/QCO.0000000000000034

DOI
10.1097/QCO.0000000000000034
Journal article

Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients

Sarfo, F. S., Zhang, Y., Egan, D., Tetteh, L. A., Phillips, R., Bedu-Addo, G., . . . Chadwick, D. R. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(2), 491-499. doi:10.1093/jac/dkt372

DOI
10.1093/jac/dkt372
Journal article

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi

Dickinson, L., Chaponda, M., Carr, D. F., van Oosterhout, J. J., Kumwenda, J., Lalloo, D. G., . . . Khoo, S. H. (2014). Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(2), 706-712. doi:10.1128/AAC.02069-13

DOI
10.1128/AAC.02069-13
Journal article

<i>CYP3A4</i>*22 (c.522-191 C&gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults

Olagunju, A., Schipani, A., Siccardi, M., Egan, D., Khoo, S., Back, D., & Owen, A. (2014). <i>CYP3A4</i>*22 (c.522-191 C&gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. PHARMACOGENETICS AND GENOMICS, 24(9), 459-463. doi:10.1097/FPC.0000000000000073

DOI
10.1097/FPC.0000000000000073
Journal article

An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database)

Danjuma, M. I., Mohamad-Fadzillah, N. H., & Khoo, S. (2014). An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database). INTERNATIONAL JOURNAL OF STD & AIDS, 25(4), 273-279. doi:10.1177/0956462413504747

DOI
10.1177/0956462413504747
Journal article

Darunavir pharmacokinetics throughout pregnancy and postpartum

Lambert, J., Jackson, V., Else, L., Lawless, M., McDonald, G., Le Blanc, D., . . . Khoo, S. (2014). Darunavir pharmacokinetics throughout pregnancy and postpartum. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/

DOI
10.7448/IAS.17.4.19485
Poster

Kidney transplantation in HIV-positive adults: the UK experience

Gathogo, E. N., Hamzah, L., Hilton, R., Marshall, N., Ashley, C., Harber, M., . . . Post, F. A. (2014). Kidney transplantation in HIV-positive adults: the UK experience. INTERNATIONAL JOURNAL OF STD & AIDS, 25(1), 57-66. doi:10.1177/0956462413493266

DOI
10.1177/0956462413493266
Journal article

Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries

Hill, A. M., van de Ven, N. S., Simmons, B., Ford, N., Khoo, S. H., & Fortunak, J. M. (2014). Minimum target prices for production of Direct Acting Antivirals and associated diagnostics for developing countries. In HEPATOLOGY Vol. 60 (pp. 233A-234A). Retrieved from https://www.webofscience.com/

Conference Paper

Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome

Sloan, D. J., Schipani, A., Waterhouse, D., Stone, L., Mwandumba, H. C., Butterworth, A. E., . . . Davies, G. R. (2014). Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome. Topics in Antiviral Medicine, 22(e-1), 55. Retrieved from https://www.iasusa.org/tam/april-2014

Journal article

Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers

Singh, G. K. J., Jackson, A., D'Avolio, A., Else, L., Bonora, S., Di Perri, G., . . . Boffito, M. (2014). Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers. HIV MEDICINE, 15, 115. Retrieved from https://www.webofscience.com/

Journal article

Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry

Else, L. J., Tjia, J., Jackson, A., Penchala, S. D., Egan, D., Boffito, M., . . . Back, D. J. (2014). Quantification of rilpivirine in human plasma, cervicovaginal fluid, rectal fluid and genital/rectal mucosal tissues using liquid chromatography-tandem mass spectrometry. BIOANALYSIS, 6(14), 1907-1921. doi:10.4155/BIO.14.59

DOI
10.4155/BIO.14.59
Journal article

Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi

Geretti, A. M., Aoudjane, S., Chaponda, M., Gonzalez del Castillo, A., O'Connor, J., Noguera, M., . . . van Oosterhout, J. (2014). Severe virologic expression of hepatitis B virus (HBV) co-infection in HIV-positive adults starting antiretroviral therapy (ART) in Malawi. In ANTIVIRAL THERAPY Vol. 19 (pp. A36). Retrieved from https://www.webofscience.com/

Conference Paper

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. J Int AIDS Soc, 17(4 Supp), 19583.

Journal article

Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors?

Hill, A., Khoo, S., Back, D., Pozniak, A., & Boffito, M. (2014). Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors?. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17, 64-65. doi:10.7448/IAS.17.4.19583

DOI
10.7448/IAS.17.4.19583
Journal article

Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations

El-Sherif, O., Penchala, S. D., Else, L. J., Norris, S., & Khoo, S. H. (2014). Significant interindividual variability in Telaprevir exposure in patients undergoing anti-HCV therapy - need for "real world" PK studies to identify vulnerable populations. In HEPATOLOGY Vol. 60 (pp. 689A). Retrieved from https://www.webofscience.com/

Conference Paper

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. J Int AIDS Soc, 17(4 Supp), 19586.

Journal article

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.

Dickinson, L., Winston, A., Boffito, M., Khoo, S., Back, D., & Siccardi, M. (2014). Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.. Journal of the International AIDS Society, 17(4 Suppl 3), 19586. doi:10.7448/ias.17.4.19586

DOI
10.7448/ias.17.4.19586
Journal article

Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update)

Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Youle, M. (2014). Special Issue: British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (2013 update). HIV MEDICINE, 15, 1-85. doi:10.1111/hiv.12119

DOI
10.1111/hiv.12119
Journal article

Who accesses PrEP? An analysis of baseline data in the PROUD pilot

Dolling, D., Desai, M., Saunders, J., Mackie, N., McOwan, A., Youssef, E., . . . McCormack, S. (2014). Who accesses PrEP? An analysis of baseline data in the PROUD pilot. HIV MEDICINE, 15, 15. Retrieved from https://www.webofscience.com/

Journal article

2013

Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation

Liptrott, N. J., Curley, P., Moss, D., Back, D. J., Khoo, S. H., & Owen, A. (2013). Interactions between tenofovir and nevirapine in CD4+T cells and monocyte-derived macrophages restrict their intracellular accumulation. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(11), 2545-2549. doi:10.1093/jac/dkt225

DOI
10.1093/jac/dkt225
Journal article

New Drugs and Treatment Regimens

Sloan, D., Davies, G., & Khoo, S. (2013). New Drugs and Treatment Regimens. Current Respiratory Medicine Reviews, 9(3), 200-210. doi:10.2174/1573398x113099990017

DOI
10.2174/1573398x113099990017
Journal article

Opinion: The Pharmacometrics of Infectious Disease

Davies, G. R., Hope, W., & Khoo, S. (2013). Opinion: The Pharmacometrics of Infectious Disease. CPT: Pharmacometrics &amp; Systems Pharmacology, 2(8), 1-3. doi:10.1038/psp.2013.46

DOI
10.1038/psp.2013.46
Journal article

Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.

Westwood, T. D., Hogan, C., Julyan, P. J., Coutts, G., Bonington, S., Carrington, B., . . . Bonington, A. (2013). Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.. European journal of radiology, 82(8), e374-e379. doi:10.1016/j.ejrad.2013.03.008

DOI
10.1016/j.ejrad.2013.03.008
Journal article

Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer

Penchala, S. D., Tjia, J., El Sherif, O., Back, D. J., Khoo, S. H., & Else, L. J. (2013). Validation of an electrospray ionisation LC-MS/MS method for quantitative analysis of telaprevir and its R-diastereomer. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 932, 100-110. doi:10.1016/j.jchromb.2013.06.013

DOI
10.1016/j.jchromb.2013.06.013
Journal article

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

Siccardi, M., Marzolini, C., Seden, K., Almond, L., Kirov, A., Khoo, S., . . . Back, D. (2013). Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. CLINICAL PHARMACOKINETICS, 52(7), 583-592. doi:10.1007/s40262-013-0056-7

DOI
10.1007/s40262-013-0056-7
Journal article

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston, A., Jose, S., Gibbons, S., Back, D., Stohr, W., Post, F., . . . UK Collaborative HIV Cohort Study. (2013). Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.. The Journal of antimicrobial chemotherapy, 68(6), 1354-1359. doi:10.1093/jac/dkt029

DOI
10.1093/jac/dkt029
Journal article

Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.

Mora-Peris, B., Croucher, A., Else, L. J., Vera, J. H., Khoo, S., Scullard, G., . . . Winston, A. (2013). Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.. The Journal of antimicrobial chemotherapy, 68(6), 1348-1353. doi:10.1093/jac/dkt006

DOI
10.1093/jac/dkt006
Journal article

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population

Carr, D. F., Chaponda, M., Jorgensen, A. L., Castro, E. C., van Oosterhout, J. J., Khoo, S. H., . . . Pirmohamed, M. (2013). Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population. CLINICAL INFECTIOUS DISEASES, 56(9), 1330-1339. doi:10.1093/cid/cit021

DOI
10.1093/cid/cit021
Journal article

Rilpivirine concentrations in seminal plasma in HIV infected patients

Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.

Poster

Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment

Lamorde, M., Byakika-Kibwika, P., Mayito, J., Nabukeera, L., Ryan, M., Hanpithakpong, W., . . . Merry, C. (2013). Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS, 27(6), 961-965. doi:10.1097/QAD.0b013e32835cae3b

DOI
10.1097/QAD.0b013e32835cae3b
Journal article

Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.

Seden, K., Khoo, S., Back, D., Prevatt, N., Lamorde, M., Byakika-Kibwika, P., . . . Merry, C. (2013). Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.. AIDS (London, England), 27(5), 675-686. doi:10.1097/qad.0b013e32835ca9b4

DOI
10.1097/qad.0b013e32835ca9b4
Journal article

The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence.

Seden, K., Bradley, M., Miller, A. R. O., Beadsworth, M. B. J., & Khoo, S. H. (2013). The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence.. International journal of STD & AIDS, 24(3), 237-241. doi:10.1177/0956462412472428

DOI
10.1177/0956462412472428
Journal article

Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England

Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., McManus, A., . . . Khoo, S. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ Open, 3(1).

Journal article

Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England

Seden, K., Kirkham, J. J., Kennedy, T., Lloyd, M., James, S., Mcmanus, A., . . . Khoo, S. H. (2013). Cross-sectional study of prescribing errors in patients admitted to nine hospitals across North West England. BMJ OPEN, 3(1). doi:10.1136/bmjopen-2012-002036

DOI
10.1136/bmjopen-2012-002036
Journal article

Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.

Seden, K., Khoo, S. H., Back, D., Byakika-Kibwika, P., Lamorde, M., Ryan, M., & Merry, C. (2013). Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.. The Journal of antimicrobial chemotherapy, 68(1), 1-3. doi:10.1093/jac/dks346

DOI
10.1093/jac/dks346
Journal article

New Drugs and Treatment Regimens for tuberculosis

Sloan, D. J., Davies, G. R., & Khoo, S. H. (2013). New Drugs and Treatment Regimens for tuberculosis. Current Respiratory Medicine Reviews, 9(3), 200-210.

Journal article

Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach

Siccardi, M., Olagunju, A., Curley, P., Hobson, J., Khoo, S., Back, D., & Owen, A. (2013). Prediction of Etravirine Pharmacogenetics using a Physiologically Based Pharmacokinetic approach. In 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, USA.

Conference Paper

Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies

Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous Population Pharmacokinetic Modelling of Atazanavir and Ritonavir in HIV-Infected Adults and Assessment of Different Dose Reduction Strategies. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

DOI
10.1097/QAI.0b013e3182737231
Journal article

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

Schipani, A., Dickinson, L., Boffito, M., Austin, R., Owen, A., Back, D., . . . Davies, G. (2013). Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies. J Acquir Immune Defic Syndr, 62(1), 60-66. doi:10.1097/QAI.0b013e3182737231

DOI
10.1097/QAI.0b013e3182737231
Journal article

The pharmacometrics of infectious diseases

Davies, G. R., Khoo, S. H., & Hope, W. (2013). The pharmacometrics of infectious diseases. CPT: Pharmacometrics and systems pharmacology, 2, e70. Retrieved from cpt:%20pharmacomet.%20syst.%20pharmacol.%202:%20e70;%20doi:10.1038/psp.2013.46

Journal article

2012

Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP)

Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336

DOI
10.7448/ias.15.6.18336
Journal article

HIV infection and stroke: current perspectives and future directions

Benjamin, L. A., Bryer, A., Emsley, H. C. A., Khoo, S., Solomon, T., & Connor, M. D. (2012). HIV infection and stroke: current perspectives and future directions. LANCET NEUROLOGY, 11(10), 878-890. doi:10.1016/S1474-4422(12)70205-3

DOI
10.1016/S1474-4422(12)70205-3
Journal article

Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of <i>SLCO1B1</i> polymorphisms on lopinavir plasma concentration in HIV-infected adults. ANTIVIRAL THERAPY, 17(5), 861-868. doi:10.3851/IMP2095

DOI
10.3851/IMP2095
Journal article

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.

Williams, I., Churchill, D., Anderson, J., Boffito, M., Bower, M., Cairns, G., . . . Youle, M. (2012). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.. HIV medicine, 13 Suppl 2, 1-85. doi:10.1111/j.1468-1293.2012.01029.x

DOI
10.1111/j.1468-1293.2012.01029.x
Journal article

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207

DOI
10.1093/jac/dks207
Journal article

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.

Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Namakula, R., Mayanja-Kizza, H., . . . Merry, C. (2012). Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(9), 2213-2221. doi:10.1093/jac/dks207

DOI
10.1093/jac/dks207
Journal article

Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings

Sloan, D. J., Corbett, E. L., Butterworth, A. E., Mwandumba, H. C., Khoo, S. H., Mdolo, A., . . . Davies, G. R. (2012). Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor Settings. JOURNAL OF CLINICAL MICROBIOLOGY, 50(7), 2315-2320. doi:10.1128/JCM.00043-12

DOI
10.1128/JCM.00043-12
Journal article

Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.

Lamorde, M., Byakika-Kibwika, P., Boffito, M., Nabukeera, L., Mayito, J., Ogwal-Okeng, J., . . . Merry, C. (2012). Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.. Journal of acquired immune deficiency syndromes (1999), 60(3), 295-298. doi:10.1097/qai.0b013e3182567a35

DOI
10.1097/qai.0b013e3182567a35
Journal article

Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>

Moss, D. M., Siccardi, M., Murphy, M., Piperakis, M. M., Khoo, S. H., Back, D. J., & Owen, A. (2012). Divalent Metals and pH Alter Raltegravir Disposition <i>In Vitro</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(6), 3020-3026. doi:10.1128/AAC.06407-11

DOI
10.1128/AAC.06407-11
Journal article

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.

Byakika-Kibwika, P., Lamorde, M., Okaba-Kayom, V., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., . . . Merry, C. (2012). Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 67(5), 1217-1223. doi:10.1093/jac/dkr596

DOI
10.1093/jac/dkr596
Journal article

Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF)

Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.

Poster

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

Else, L. J., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(3), 1427-1433. doi:10.1128/AAC.05599-11

DOI
10.1128/AAC.05599-11
Journal article

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.

Journal article

Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations

Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 56(2), 816-824. doi:10.1128/AAC.05186-11

DOI
10.1128/AAC.05186-11
Journal article

Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations

Else, L. J., Douglas, M., Dickinson, L., Back, D. J., Khoo, S. H., & Taylor, G. P. (2012). Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma Concentrations. Antimicrobial Agents and Chemotherapy, 56(2), 816-824. doi:10.1128/aac.05186-11

DOI
10.1128/aac.05186-11
Journal article

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.

Else, L., Douglas, M., Dickinson, L., Back, D., Khoo, S., & Taylor, G. P. (2012). Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.. Antimicrobial agents and chemotherapy, 56(2), 816-824.

Journal article

Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system?

Seden, K., Mathew, T., Bradley, M., Ferraro, C., Hall, E., Beeching, N. J., & Khoo, S. H. (2012). Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system?. INTERNATIONAL JOURNAL OF STD & AIDS, 23(2), 99-104. doi:10.1258/ijsa.2011.011070

DOI
10.1258/ijsa.2011.011070
Journal article

Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.. Antiviral therapy, 17(1), 19-24. doi:10.3851/imp1910

DOI
10.3851/imp1910
Journal article

Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Faetkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of <i>ABCC10</i> polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. PHARMACOGENETICS AND GENOMICS, 22(1), 10-19. doi:10.1097/FPC.0b013e32834dd82e

DOI
10.1097/FPC.0b013e32834dd82e
Journal article

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Fätkenheuer, G., Hoffmann, C., Mauss, S., . . . Owen, A. (2012). Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenetics and Genomics, 22(1), 10-19. doi:10.1097/fpc.0b013e32834dd82e

DOI
10.1097/fpc.0b013e32834dd82e
Journal article

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults

Lamorde, M., Byakika-Kibwika, P., Tamale, W. S., Kiweewa, F., Ryan, M., Amara, A., . . . Merry, C. (2012). Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. AIDS Research and Treatment, 2012, 1-6. doi:10.1155/2012/105980

DOI
10.1155/2012/105980
Journal article

Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults

Schipani, A., Egan, D., Dickinson, L., Davies, G., Boffito, M., Youle, M., . . . Owen, A. (2012). Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antiviral Therapy, 17(5), 861-868.

Journal article

Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects

Jackson, A., Moyle, G., Dickinson, L., Back, D., Khoo, S., Taylor, J., . . . Boffito, M. (2012). Pharmacokinetics of Abacavir and its Anabolite Carbovir Triphosphate without and with Darunavir/ Ritonavir or Raltegravir in HIV-Infected Subjects. Antiviral Therapy, 17(1), 19-24. doi:10.3851/imp1910

DOI
10.3851/imp1910
Journal article

Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study

Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.

Journal article

2011

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid)

Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ANTIVIRAL THERAPY, 16(8), 1139-1147. doi:10.3851/IMP1918

DOI
10.3851/IMP1918
Journal article

Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract

Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. ANTIVIRAL THERAPY, 16(8), 1149-1167. doi:10.3851/IMP1919

DOI
10.3851/IMP1919
Journal article

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67

DOI
10.1097/qai.0b013e3182364c67
Journal article

Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals

Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67

DOI
10.1097/QAI.0b013e3182364c67
Journal article

Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?

Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should We Switch to a 50-mg Boosting Dose of Ritonavir for Selected Protease Inhibitors?. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccae

DOI
10.1097/qai.0b013e318237ccae
Journal article

Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?

Hill, A., Khoo, S., Boffito, M., & Back, D. (2011). Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?. Journal of acquired immune deficiency syndromes (1999), 58(5), e137-e138. doi:10.1097/qai.0b013e318237ccae

DOI
10.1097/qai.0b013e318237ccae
Journal article

Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract

Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of Antiretroviral Drugs in Anatomical Sanctuary Sites: The Male and Female Genital Tract. Antiviral Therapy, 16(8), 1149-1167. doi:10.3851/imp1919

DOI
10.3851/imp1919
Journal article

Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents

McIlleron, H., & Khoo, S. H. (2011). Chapter 19: Interactions between Antituberculosis and Antiretroviral Agents. In Progress in Respiratory Research (pp. 191-202). S. Karger AG. doi:10.1159/000324217

DOI
10.1159/000324217
Chapter

13 A‐Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1)

Weston, R., & Khoo, S. (2011). 13 A‐Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1). HIV Medicine, 12(s2), 112-139. doi:10.1111/j.1468-1293.2011.00944_14.x

DOI
10.1111/j.1468-1293.2011.00944_14.x
Journal article

Ageing with HIV: medication use and risk for potential drug-drug interactions

Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Yerly, S. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248

DOI
10.1093/jac/dkr248
Journal article

British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.

Nelson, M., Dockrell, D., Edwards, S., BHIVA Guidelines Subcommittee., Angus, B., Barton, S., . . . Weston, R. (2011). British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.. HIV medicine, 12 Suppl 2, 1-140. doi:10.1111/j.1468-1293.2011.00944_1.x

DOI
10.1111/j.1468-1293.2011.00944_1.x
Journal article

Interactions between antituberculosis and antiretroviral agents

McIlleron, H., & Khoo, S. H. (2011). Interactions between antituberculosis and antiretroviral agents (Vol. 40). doi:10.1159/000324217

DOI
10.1159/000324217
Book

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. Antimicrobial Agents and Chemotherapy, 55(9), 4218-4223. doi:10.1128/aac.01747-10

DOI
10.1128/aac.01747-10
Journal article

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

Boffito, M., Jackson, A., Amara, A., Back, D., Khoo, S., Higgs, C., . . . Moyle, G. (2011). Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(9), 4218-4223. doi:10.1128/AAC.01747-10

DOI
10.1128/AAC.01747-10
Journal article

Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

Pushpakom, S. P., Liptrott, N. J., Rodriguez-Novoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of <i>ABCC10</i>, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. JOURNAL OF INFECTIOUS DISEASES, 204(1), 145-153. doi:10.1093/infdis/jir215

DOI
10.1093/infdis/jir215
Journal article

Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction

Pushpakom, S. P., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2011). Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. The Journal of Infectious Diseases, 204(1), 145-153. doi:10.1093/infdis/jir215

DOI
10.1093/infdis/jir215
Journal article

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . Back, D. J. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 66(6), 1332-1339. doi:10.1093/jac/dkr087

DOI
10.1093/jac/dkr087
Journal article

Lopinavir/ritonavir population pharmacokinetics in neonates and infants

Urien, S., Firtion, G., Anderson, S. T., Hirt, D., Solas, C., Peytavin, G., . . . Tréluyer, J. (2011). Lopinavir/ritonavir population pharmacokinetics in neonates and infants. British Journal of Clinical Pharmacology, 71(6), 956-960. doi:10.1111/j.1365-2125.2011.03926.x

DOI
10.1111/j.1365-2125.2011.03926.x
Journal article

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6), 2775-2782. doi:10.1128/AAC.00887-10

DOI
10.1128/AAC.00887-10
Journal article

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies. Antimicrobial Agents and Chemotherapy, 55(6), 2775-2782. doi:10.1128/aac.00887-10

DOI
10.1128/aac.00887-10
Journal article

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults

Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults. Chemotherapy Research and Practice, 2011, 1-4. doi:10.1155/2011/393976

DOI
10.1155/2011/393976
Journal article

Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.

Byakika-Kibwika, P., Lamorde, M., Lwabi, P., Nyakoojo, W. B., Okaba-Kayom, V., Mayanja-Kizza, H., . . . Merry, C. (2011). Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.. Chemotherapy research and practice, 2011, 393976. doi:10.1155/2011/393976

DOI
10.1155/2011/393976
Journal article

Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

Byakika-Kibwika, P., Lamorde, M., Mayanja-Kizza, H., Khoo, S., Merry, C., & Van Geertruyden, J. -P. (2011). Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.. Malaria research and treatment, 2011, 703730. doi:10.4061/2011/703730

DOI
10.4061/2011/703730
Journal article

Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology

Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.

Poster

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. The Journal of antimicrobial chemotherapy, 66(3), 635-640. doi:10.1093/jac/dkq468

DOI
10.1093/jac/dkq468
Journal article

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

Lambert, J. S., Else, L. J., Jackson, V., Breiden, J., Gibbons, S., Dickinson, L., . . . Khoo, S. H. (2011). Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Medicine, 12(3), 166-173. doi:10.1111/j.1468-1293.2010.00865.x

DOI
10.1111/j.1468-1293.2010.00865.x
Journal article

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort

Kigen, G., Kimaiyo, S., Nyandiko, W., Faragher, B., Sang, E., Jakait, B., . . . Khoo, S. H. (2011). Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. PLOS ONE, 6(2). doi:10.1371/journal.pone.0016800

DOI
10.1371/journal.pone.0016800
Journal article

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2011). Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 879-887. doi:10.1128/AAC.00623-10

DOI
10.1128/AAC.00623-10
Journal article

Ageing with HIV: medication use and risk for potential drug-drug interactions.

Marzolini, C., Back, D., Weber, R., Furrer, H., Cavassini, M., Calmy, A., . . . Swiss HIV Cohort Study Members. (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions.. The Journal of antimicrobial chemotherapy, 66(9), 2107-2111. doi:10.1093/jac/dkr248

DOI
10.1093/jac/dkr248
Journal article

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., . . . for HIV/AIDS, G. C. N. (2011). Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.. J Antimicrob Chemother, 66(6), 1332-1339.

Journal article

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin

Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Ryan, M., Coakley, P., Boffito, M., . . . Merry, C. (2011). Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Journal of Antimicrobial Chemotherapy, 66(1), 180-183. doi:10.1093/jac/dkq411

DOI
10.1093/jac/dkq411
Journal article

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2011). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother, 66(3), 635-640.

Journal article

Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals

Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. J Acquir Immune Defic Syndr, 58(5), 450-457. doi:10.1097/QAI.0b013e3182364c67

DOI
10.1097/QAI.0b013e3182364c67
Journal article

Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.

Dickinson, L., Boffito, M., Back, D., Else, L., von Hentig, N., Davies, G., . . . Aarons, L. (2011). Sequential population pharmacokinetic modelling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.. Antimicrob Agents Chemother, 55(6), 2775-2782.

Journal article

The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir

Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir. Int J STD AIDS, 22, 11-14.

Journal article

The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir.

Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). The utility of Therapeutic Drug Monitoring (TDM) in the management of HIV infected pregnant women in receipt of lopinavir.. Int J STD AIDS, 22, 11-14.

Journal article

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir

Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. International Journal of STD &amp; AIDS, 22(1), 11-14. doi:10.1258/ijsa.2009.009184

DOI
10.1258/ijsa.2009.009184
Journal article

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.

Caswell, R. J., Phillips, D., Chaponda, M., Khoo, S. H., Taylor, G. P., Ghanem, M., . . . Lambert, J. S. (2011). Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.. International journal of STD & AIDS, 22(1), 11-14. doi:10.1258/ijsa.2009.009184

DOI
10.1258/ijsa.2009.009184
Journal article

2010

Grapefruit-Drug Interactions

Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit-Drug Interactions. Drugs, 70(18), 2373-2407. doi:10.2165/11585250-000000000-00000

DOI
10.2165/11585250-000000000-00000
Journal article

Pharmacokinetic evaluation of etravirine

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetic evaluation of etravirine. Expert Opinion on Drug Metabolism &amp; Toxicology, 6(12), 1575-1585. doi:10.1517/17425255.2010.535811

DOI
10.1517/17425255.2010.535811
Journal article

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. Antimicrobial Agents and Chemotherapy, 54(12), 5242-5250. doi:10.1128/aac.00781-10

DOI
10.1128/aac.00781-10
Journal article

Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance

Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population Pharmacokinetic Modeling of the Association between 63396C→T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(12), 5242-5250. doi:10.1128/AAC.00781-10

DOI
10.1128/AAC.00781-10
Journal article

Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women

Lamorde, M., Byakika-Kibwika, P., Okaba-Kayom, V., Flaherty, J. P., Boffito, M., Namakula, R., . . . Scarsi, K. K. (2010). Suboptimal Nevirapine Steady-State Pharmacokinetics During Intrapartum Compared With Postpartum in HIV-1-Seropositive Ugandan Women. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 55(3), 345-350. doi:10.1097/QAI.0b013e3181e9871b

DOI
10.1097/QAI.0b013e3181e9871b
Journal article

Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults

Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . Khoo, S. (2010). Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults. Antimicrobial Agents and Chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09

DOI
10.1128/aac.01198-09
Journal article

Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease

Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., Khoo, S., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax, 65(6), 559-570. doi:10.1136/thx.2009.133173

DOI
10.1136/thx.2009.133173
Journal article

Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.

British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee., Milburn, H., Ashman, N., Davies, P., Doffman, S., Drobniewski, F., . . . Snelson, C. (2010). Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.. Thorax, 65(6), 557-570. doi:10.1136/thx.2009.133173

DOI
10.1136/thx.2009.133173
Journal article

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals

Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. Journal of Antimicrobial Chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086

DOI
10.1093/jac/dkq086
Journal article

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds

Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036

DOI
10.1016/j.jchromb.2010.03.036
Journal article

Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy

Evans-Jones, J. G., Cottle, L. E., Back, D. J., Gibbons, S., Beeching, N. J., Carey, P. B., & Khoo, S. H. (2010). Recognition of Risk for Clinically Significant Drug Interactions among HIV-Infected Patients Receiving Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES, 50(10), 1419-1421. doi:10.1086/652149

DOI
10.1086/652149
Journal article

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Mackie, N. E., Phillips, A. N., Kaye, S., Booth, C., & Geretti, A. -M. (2010). Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.. The Journal of infectious diseases, 201(9), 1303-1307. doi:10.1086/651618

DOI
10.1086/651618
Journal article

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. Journal of Antimicrobial Chemotherapy, 65(5), 906-916. doi:10.1093/jac/dkq082

DOI
10.1093/jac/dkq082
Journal article

Tenofovir Disoproxil Fumarate and the Kidney in Hiv-Infected Patients: The Evidence Thus Far

Danjuma, M. I., Mohiuddin, A., Pirmohamed, M., & Khoo, S. (2010). Tenofovir Disoproxil Fumarate and the Kidney in Hiv-Infected Patients: The Evidence Thus Far. HIV Therapy, 4(3), 345-359. doi:10.2217/hiv.10.16

DOI
10.2217/hiv.10.16
Journal article

Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study

Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Battegay, M. (2010). Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3), 413-423. doi:10.3851/imp1540

DOI
10.3851/imp1540
Journal article

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. The Journal of antimicrobial chemotherapy, 65(6), 1079-1085. doi:10.1093/jac/dkq086

DOI
10.1093/jac/dkq086
Journal article

Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Bray, P. G., Jones, E., Wyen, C., Chiba, P., Back, D. J., & Khoo, S. H. (2010). Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(5), 906-916. doi:10.1093/jac/dkq082

DOI
10.1093/jac/dkq082
Journal article

Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans

Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A. -B., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(2), 316-319. doi:10.1093/jac/dkp451

DOI
10.1093/jac/dkp451
Journal article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms

Hartkoorn, R. C., San Kwan, W., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by <i>SLCO1B1</i> polymorphisms. PHARMACOGENETICS AND GENOMICS, 20(2), 112-120. doi:10.1097/FPC.0b013e328335b02d

DOI
10.1097/FPC.0b013e328335b02d
Journal article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms

Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenetics and Genomics, 20(2), 112-120. doi:10.1097/fpc.0b013e328335b02d

DOI
10.1097/fpc.0b013e328335b02d
Journal article

Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS

Liptrott, N. J., Pushpakom, S., Wyen, C., Rockstroh, J., Mauss, S., Knechten, H., . . . Owen, A. (2010). Association of ABCC10 Polymorphisms with Nevirapine Plasma Concentrations in the German Competence Network for HIV/AIDS. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 286). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.

Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.. J Antimicrobial Chemother, 65(2), 316-319.

Journal article

Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens

Pushpakom, S., Liptrott, N. J., Rodríguez-Nóvoa, S., Labarga, P., Soriano, V., Albalater, M., . . . Owen, A. (2010). Genetic Variants of ABCC10 Are Associated with Kidney Tubular Dysfunction in Patients Treated with Tenofovir-containing Regimens. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 352). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Grapefruit juice drug interactions

Seden, K., Dickinson, L., Khoo, S., & Back, D. (2010). Grapefruit juice drug interactions. Drugs, 70(18), 2373-2407.

Journal article

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., . . . Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.. Pharmacogenet Genomics, 20(2), 112-120.

Journal article

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

Seden, K., Back, D., & Khoo, S. (2010). New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.. J Antimicrob Chemother, 65(6), 1079-1085.

Journal article

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-

Paediatric European Network for Treatment of AIDS PENTA Group au. (2010). Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-. Antivir Ther, 15(3), 297-305.

Journal article

Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.

Dickinson, L., Khoo, S., & Back, D. (2010). Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.. Antiviral research, 85(1), 176-189.

Journal article

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . DART Trial Team. (2010). Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.. Antimicrobial agents and chemotherapy, 54(7), 2965-2973. doi:10.1128/aac.01198-09

DOI
10.1128/aac.01198-09
Journal article

Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults

Kityo, C., Walker, A. S., Dickinson, L., Lutwama, F., Kayiwa, J., Ssali, F., . . . on behalf of the DART trial team. (2010). Pharmacokinetics of lopinavir/ritonavir with and without non-nucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Antimicrob Agents Chemother, 54(7), 2965-2973.

Journal article

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

Jackson, A., Hill, A., Puls, R., Else, L., Amin, J., Back, D., . . . Boffito, M. (2010). Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.. J Antimicrob Chemother..

Journal article

Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance

Schipani, A., Siccardi, M., D'Avolio, A., Baietto, L., Simiele, M., Bonora, S., . . . Owen, A. (2010). Population pharmacokinetic modelling of the association between 63396C->T Pregnane X Receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother, 54(12), 5242-5250.

Journal article

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.

Marzolini, C., Elzi, L., Gibbons, S., Weber, R., Fux, C., Furrer, H., . . . Swiss HIV Cohort Study. (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.. Antiviral therapy, 15(3), 413-423. doi:10.3851/imp1540

DOI
10.3851/imp1540
Journal article

Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2

Moss, D., Kwan, W., Liptrott, N., Siccardi, M., Anstee, D., Khoo, S., . . . Owen, A. (2010). Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2. In 17th Conference on Retroviruses and Opportunistic Infections (pp. 293). San Francisco: Conference on Retroviruses and Opportunistic Infections.

Conference Paper

Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir

Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother, 55(2), 879-887.

Journal article

Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.

Moss, D. M., Kwan, W. S., Liptrott, N. J., Smith, D. L., Siccardi, M., Khoo, S. H., . . . Owen, A. (2010). Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir.. Antimicrob Agents Chemother, 55(2), 879-887.

Journal article

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS. Group authors., & Khoo, S. (2010). Response to planned treatment interruptions in HIV infection varies across childhood.. AIDS., 24(2), 231-241.

Journal article

Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.

Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.. Antiviral therapy, 15(3), 343-350. doi:10.3851/imp1544

DOI
10.3851/imp1544
Journal article

Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.

Poerksen, G., Pollock, L., Moons, P., Chesshyre, E., Burger, D., Khoo, S., & Molyneux, E. (2010). Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.. Antivir Ther, 15(2), 343-350.

Journal article

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.. J Chromatogr B Analyt Technol Biomed Life Sci, 878(19), 1455-1465.

Journal article

2009

P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir

Janneh, O., Anwar, T., Jungbauer, C., Kopp, S., Khoo, S. H., Back, D. J., & Chiba, P. (2009). P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. ANTIVIRAL THERAPY, 14(7), 965-974. doi:10.3851/IMP1399

DOI
10.3851/IMP1399
Journal article

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.

Pollock, L., Else, L., Poerksen, G., Molyneux, E., Moons, P., Walker, S., . . . Khoo, S. (2009). Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.. The Journal of antimicrobial chemotherapy, 64(6), 1251-1259. doi:10.1093/jac/dkp358

DOI
10.1093/jac/dkp358
Journal article

Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. H. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 64(5), 1002-1007. doi:10.1093/jac/dkp335

DOI
10.1093/jac/dkp335
Journal article

Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Chandler, B., Hartkoorn, R., Kwan, W. S., Jenkinson, C., Evans, S., . . . Khoo, S. (2009). Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother, 64(5), 1002-1007.

Journal article

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

Mahungu, T., Smith, C., Turner, F., Egan, D., Youle, M., Johnson, M., . . . Owen, A. (2009). Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med, 10(5), 310-317.

Journal article

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 68(3), 375-380. doi:10.1111/j.1365-2125.2009.03462.x

DOI
10.1111/j.1365-2125.2009.03462.x
Journal article

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

Kwan, W. S., Janneh, O., Hartkoorn, R., Chandler, B., Khoo, S., Back, D., & Owen, A. (2009). Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC. Br J Clin Pharmacol, 68(3), 375-380.

Journal article

The Relationships of ABCB1 3435C&gt;T and CYP2B6 516G&gt;T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz

Mahungu, T. W., Nair, D., Smith, C. J., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). The Relationships of ABCB1 3435C&gt;T and CYP2B6 516G&gt;T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. CLINICAL PHARMACOLOGY & THERAPEUTICS, 86(2), 204-211. doi:10.1038/clpt.2009.78

DOI
10.1038/clpt.2009.78
Journal article

Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.

Seden, K., Back, D., & Khoo, S. (2009). Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable.. The Journal of antimicrobial chemotherapy, 64(1), 5-8. doi:10.1093/jac/dkp152

DOI
10.1093/jac/dkp152
Journal article

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Journal of Antimicrobial Chemotherapy, 63(6), 1233-1243. doi:10.1093/jac/dkp102

DOI
10.1093/jac/dkp102
Journal article

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study

Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. CLINICAL INFECTIOUS DISEASES, 48(11), E108-E116. doi:10.1086/598507

DOI
10.1086/598507
Journal article

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

Dickinson, L., Boffito, M., Back, D., Waters, L., Else, L., Davies, G., . . . Aarons, L. (2009). Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 63(6), 1233-1243. doi:10.1093/jac/dkp102

DOI
10.1093/jac/dkp102
Journal article

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

Mahungu, T. W., Smith, C. J., Turner, F., Egan, D., Youle, M., Johnson, M. A., . . . Owen, A. (2009). Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV MEDICINE, 10(5), 310-317. doi:10.1111/j.1468-1293.2008.00689.x

DOI
10.1111/j.1468-1293.2008.00689.x
Journal article

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. British Journal of Pharmacology, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x

DOI
10.1111/j.1476-5381.2008.00050.x
Journal article

The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC

Liptrott, N. J., Penny, M., Bray, P. G., Sathish, J., Khoo, S. H., Back, D. J., & Owen, A. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. BRITISH JOURNAL OF PHARMACOLOGY, 156(3), 497-508. doi:10.1111/j.1476-5381.2008.00050.x

DOI
10.1111/j.1476-5381.2008.00050.x
Journal article

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

Dickinson, L., Khoo, S., & Back, D. (2009). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV & AIDS, (in pr.

Journal article

Drug-Drug Interactions Involving Antiretrovirals

Seden, K., Back, D. J., & Khoo, S. H. (2009). Drug-Drug Interactions Involving Antiretrovirals. Journal of Antimicrobial Chemotherapy, (in pr.

Journal article

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

Rodriguez-Novoa, S., Labarga, P., Soriano, V., Egan, D., Albalater, M., Morello, J., . . . Owen, A. (2009). Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis, 48(11), e108-e116.

Journal article

2008

Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry

Liprott, N. J., Khoo, S. H., Back, D. J., & Owen, A. (2008). Detection of ABCC2, CYP2B6 and CYP3A4 in human peripheral blood mononuclear cells using flow cytometry. JOURNAL OF IMMUNOLOGICAL METHODS, 339(2), 270-274. doi:10.1016/j.jim.2008.09.010

DOI
10.1016/j.jim.2008.09.010
Journal article

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

Boffito, M., Else, L., Back, D., Taylor, J., Khoo, S., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.. Antiviral therapy, 13(7), 901-907. doi:10.1177/135965350801300702

DOI
10.1177/135965350801300702
Journal article

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

Dickinson, L., Boffito, M., Back, D., Khoo, S., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.. The Journal of antimicrobial chemotherapy, 62(6), 1344-1355.

Journal article

Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals

Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., . . . Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(6), 1344-1355. doi:10.1093/jac/dkn399

DOI
10.1093/jac/dkn399
Journal article

Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir

Siccardi, M., D'Avolio, A., Baietto, L., Gibbons, S., Sciandra, M., Colucci, D., . . . Owen, A. (2008). Association of a single-nucleotide polymorphism in the pregnane X receptor (<i>PXR</i> 63396C→T) with reduced concentrations of unboosted atazanavir. CLINICAL INFECTIOUS DISEASES, 47(9), 1222-1225. doi:10.1086/592304

DOI
10.1086/592304
Journal article

Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?

Winston, A., & Khoo, S. (2008). Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?. Current opinion in HIV and AIDS, 3(6), 608-611. doi:10.1097/coh.0b013e328312972e

DOI
10.1097/coh.0b013e328312972e
Journal article

Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir

Janneh, O., Hartkoorn, R. C., Jones, E., Owen, A., Ward, S. A., Davey, R., . . . Khoo, S. H. (2008). Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. BRITISH JOURNAL OF PHARMACOLOGY, 155(6), 875-883. doi:10.1038/bjp.2008.320

DOI
10.1038/bjp.2008.320
Journal article

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

Moltó, J., Santos, J. R., Pérez-Alvarez, N., Cedeño, S., Miranda, C., Khoo, S., . . . Clotet, B. (2008). Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.. Antimicrobial agents and chemotherapy, 52(11), 3928-3932. doi:10.1128/aac.00520-08

DOI
10.1128/aac.00520-08
Journal article

Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.

Byakika-Kibwika, P., Lamorde, M., Kalemeera, F., D'Avolio, A., Mauro, S., Di Perri, G., . . . Merry, C. (2008). Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.. The Journal of antimicrobial chemotherapy, 62(5), 1113-1117. doi:10.1093/jac/dkn290

DOI
10.1093/jac/dkn290
Journal article

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

Gazzard, B. G., Anderson, J., Babiker, A., Boffito, M., Brook, G., Brough, G., . . . BHIVA Treatment Guidelines Writing Group. (2008). British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.. HIV medicine, 9(8), 563-608. doi:10.1111/j.1468-1293.2008.00636.x

DOI
10.1111/j.1468-1293.2008.00636.x
Journal article

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . UK CHIC Study. (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.. Antiviral therapy, 13(5), 675-685. doi:10.1177/135965350801300507

DOI
10.1177/135965350801300507
Journal article

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (n.d.). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. Journal of Antimicrobial Chemotherapy, 62(1), 161-167. doi:10.1093/jac/dkn187

DOI
10.1093/jac/dkn187
Journal article

Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing

Dickinson, L., Boffito, M., Khoo, S. H., Schutz, M., Aarons, L. J., Pozniak, A. L., & Back, D. J. (2008). Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 62(1), 161-167. doi:10.1093/jac/dkn187

DOI
10.1093/jac/dkn187
Journal article

HIV induces deletion of T cell receptor variable gene product-specific T cells.

Bansal, A. S., Green, L. M., Khoo, S. H., Pumphrey, R. S., Haeney, M. R., & Mandal, B. K. (1993). HIV induces deletion of T cell receptor variable gene product-specific T cells.. Clinical and experimental immunology, 94(1), 17-20. doi:10.1111/j.1365-2249.1993.tb05970.x

DOI
10.1111/j.1365-2249.1993.tb05970.x
Journal article

Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.. Therapeutic drug monitoring, 30(3), 306-313.

Journal article

Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313. doi:10.1097/FTD.0b013e318177209e

DOI
10.1097/FTD.0b013e318177209e
Journal article

Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis

Micheli, V., Regazzi, M., Dickinson, L., Meraviglia, P., Villani, P., Khoo, S. H., . . . Cargnel, A. (2008). Lopinavir/ritonavir pharmacokinetics in HN/HCV-coinfected patients with or without cirrhosis. THERAPEUTIC DRUG MONITORING, 30(3), 306-313.

Journal article

Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.

Cressey, T. R., Green, H., Khoo, S., Treluyer, J. -M., Compagnucci, A., Saidi, Y., . . . Paediatric European Network for Treatment of AIDS II Study Group. (2008). Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 46(10), 1601-1608. doi:10.1086/587657

DOI
10.1086/587657
Journal article

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons

Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Current Opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/coh.0b013e3282f82bf1

DOI
10.1097/coh.0b013e3282f82bf1
Journal article

Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.

Dickinson, L., Khoo, S., & Back, D. (2008). Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.. Current opinion in HIV and AIDS, 3(3), 296-305. doi:10.1097/coh.0b013e3282f82bf1

DOI
10.1097/coh.0b013e3282f82bf1
Journal article

Pharmacogenetics of antiretroviral agents

Owen, A., & Khoo, S. H. (2008). Pharmacogenetics of antiretroviral agents. CURRENT OPINION IN HIV AND AIDS, 3(3), 288-295. doi:10.1097/COH.0b013e3282f7cda4

DOI
10.1097/COH.0b013e3282f7cda4
Journal article

Impact of <i>CYP2B6</i> 983T&gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

Wyen, C., Hendra, H., Vogel, M., Hoffmann, C., Knechten, H., Brockmeyer, N. H., . . . Owen, A. (2008). Impact of <i>CYP2B6</i> 983T&gt;C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 61(4), 914-918. doi:10.1093/jac/dkn029

DOI
10.1093/jac/dkn029
Journal article

Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi.

Beadsworth, M. B. J., van Oosterhout, J. J., Diver, M. J., Faragher, E. B., Shenkin, A., Mwandumba, H. C., . . . Zijlstra, E. E. (2008). Hypoadrenalism is not associated with early mortality during tuberculosis treatment in Malawi.. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 12(3), 314-318.

Journal article

Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication

Stöhr, W., Back, D., Dunn, D., Sabin, C., Winston, A., Gilson, R., . . . Khoo, S. (2008). Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight, and Co-Medication. Antiviral Therapy, 13(5), 675-685.

Journal article

Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation

Back, D., Else, L., Khoo, S., Boffito, M., Taylor, J., Sousa, M., . . . Moyle, G. (2008). Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. ANTIVIRAL THERAPY, 13(7), 901-907.

Journal article

2007

Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes

Janneh, O., Jones, E., Chandler, B., Owen, A., & Khoo, S. H. (2007). Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(5), 987-993. doi:10.1093/jac/dkm353

DOI
10.1093/jac/dkm353
Journal article

Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification

Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., & Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(4), 881-884. doi:10.1093/jac/dkm281

DOI
10.1093/jac/dkm281
Journal article

A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin

Hartkoorn, R. C., Khoo, S., Back, D. J., Tjia, J. F., Waitt, C. J., Chaponda, M., . . . Ward, S. A. (2007). A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 857(1), 76-82. doi:10.1016/j.jchromb.2007.07.005

DOI
10.1016/j.jchromb.2007.07.005
Journal article

Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects

Chandler, B., Detsika, M., Khoo, S. H., Williams, J., Back, D. J., & Owen, A. (2007). Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60(3), 685-689. doi:10.1093/jac/dkm230

DOI
10.1093/jac/dkm230
Journal article

Stopping antiretroviral therapy.

Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy.. AIDS (London, England), 21(13), 1673-1682. doi:10.1097/qad.0b013e3281c61394

DOI
10.1097/qad.0b013e3281c61394
Journal article

Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>

Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance <i>in vitro</i>. ANTIVIRAL THERAPY, 12(5), 831-834. Retrieved from https://www.webofscience.com/

Journal article

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367. doi:10.1097/ftd.0b013e3180683b25

DOI
10.1097/ftd.0b013e3180683b25
Journal article

Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.

Dickinson, L., Back, D., Pozniak, A., Khoo, S., & Boffito, M. (2007). Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.. Therapeutic drug monitoring, 29(3), 361-367.

Journal article

Combining resistance and pharmacology for optimum patient care

Khoo, S. H., Winston, A., & Back, D. J. (2007). Combining resistance and pharmacology for optimum patient care. CURRENT OPINION IN HIV AND AIDS, 2(3), 157-168. doi:10.1097/COH.0b013e3280f31d27

DOI
10.1097/COH.0b013e3280f31d27
Journal article

Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein

Hartkoorn, R. C., Chandler, B., Owen, A., Ward, S. A., Squire, S. B., Back, D. J., & Khoo, S. H. (2007). Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. TUBERCULOSIS, 87(3), 248-255. doi:10.1016/j.tube.2006.12.001

DOI
10.1016/j.tube.2006.12.001
Journal article

Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.

Kikaire, B., Khoo, S., Walker, A. S., Ssali, F., Munderi, P., Namale, L., . . . DART Trial Team. (2007). Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.. AIDS (London, England), 21(6), 733-737. doi:10.1097/qad.0b013e3280121801

DOI
10.1097/qad.0b013e3280121801
Journal article

Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'

Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2007). Continued correspondence 'Will ART rollout in Africa drive an epidemic of drug-resistant HIV?'. AIDS, 21(2), 258-259. doi:10.1097/QAD.0b013e32801121fb

DOI
10.1097/QAD.0b013e32801121fb
Journal article

Effect of transporter modulation on the emergence of nelfinavir resistance in vitro

Chandler, B., Detsika, M., Owen, A., Evans, S., Hartkoorn, R. C., Cane, P. A., . . . Khoo, S. H. (2007). Effect of transporter modulation on the emergence of nelfinavir resistance in vitro. Antivir Ther, 12(5), 831-834. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17713167

Journal article

HIV and pharmacogenomics in 2007.

Khoo, S. (2007). HIV and pharmacogenomics in 2007.. Pharmacogenomics, 8(1), 25-27. doi:10.2217/14622416.8.1.25

DOI
10.2217/14622416.8.1.25
Journal article

Stopping antiretroviral therapy

Taylor, S., Boffito, M., Khoo, S., Smit, E., & Back, D. (2007). Stopping antiretroviral therapy. AIDS, 21(13), 1673-1682. doi:10.1097/QAD.0b013e3281c61394

DOI
10.1097/QAD.0b013e3281c61394
Journal article

2006

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

Friedland, G., Khoo, S., Jack, C., & Lalloo, U. (2006). Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.. The Journal of antimicrobial chemotherapy, 58(6), 1299-1302. doi:10.1093/jac/dkl399

DOI
10.1093/jac/dkl399
Journal article

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

Ford, J., Boffito, M., Maitland, D., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2006). Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.. The Journal of antimicrobial chemotherapy, 58(5), 1009-1016. doi:10.1093/jac/dkl379

DOI
10.1093/jac/dkl379
Journal article

No room for complacency on drug resistance in Africa

Hastings, I. M., Lalloo, D. G., & Khoo, S. H. (2006). No room for complacency on drug resistance in Africa. NATURE, 444(7115), 31. doi:10.1038/444031c

DOI
10.1038/444031c
Journal article

Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug

Hider, S. L., Owen, A., Hartkoorn, R., Khoo, S., Back, D., Silman, A. J., & Bruce, I. N. (2006). Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug. ANNALS OF THE RHEUMATIC DISEASES, 65(10), 1390-1393. doi:10.1136/ard.2005.049189

DOI
10.1136/ard.2005.049189
Journal article

Pharmacogenetics of HIV therapy

Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. PHARMACOGENETICS AND GENOMICS, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57

DOI
10.1097/01.fpc.0000236338.41799.57
Journal article

Optimal sampling strategies for early pharmacodynamic measures in tuberculosis

Davies, G. R., Khoo, S. H., & Aarons, L. J. (2006). Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 58(3), 594-600. doi:10.1093/jac/dkl272

DOI
10.1093/jac/dkl272
Journal article

Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment

Davies, G. R., Brindle, R., Khoo, S. H., & Aarons, L. J. (2006). Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 50(9), 3154-3156. doi:10.1128/AAC.00774-05

DOI
10.1128/AAC.00774-05
Journal article

Will ART rollout in Africa drive an epidemic of drug resistant HIV?

Hastings, I. M., Lalloo, D., & Khoo, S. H. (2006). Will ART rollout in Africa drive an epidemic of drug resistant HIV?. AIDS, 20(9), 1354-1356. doi:10.1097/01.aids.0000232257.97027.80

DOI
10.1097/01.aids.0000232257.97027.80
Journal article

An update on therapeutic drug monitoring for antiretroviral drugs.

Back, D., Gibbons, S., & Khoo, S. (2006). An update on therapeutic drug monitoring for antiretroviral drugs.. Therapeutic drug monitoring, 28(3), 468-473. doi:10.1097/01.ftd.0000211825.57984.41

DOI
10.1097/01.ftd.0000211825.57984.41
Journal article

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

Winston, A., Patel, N., Back, D., Khoo, S., Bulbeck, S., Mandalia, S., . . . Boffito, M. (2006). Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.. Journal of acquired immune deficiency syndromes (1999), 41(5), 675-676. doi:10.1097/01.qui.0000209910.27997.d9

DOI
10.1097/01.qui.0000209910.27997.d9
Journal article

Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support

Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) - A randomized controlled trial of therapeutic drug monitoring and adherence support. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 41(4), 461-467. doi:10.1097/01.qai.0000218345.65434.21

DOI
10.1097/01.qai.0000218345.65434.21
Journal article

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

Back, D. J., Owen, A., & Khoo, S. H. (2006). Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. CLINICAL PHARMACOKINETICS, 45(2), 213-214. doi:10.2165/00003088-200645020-00006

DOI
10.2165/00003088-200645020-00006
Journal article

No room for complacency on drug resistance in Africa

Hastings, I. M., Lalloo, D. G., & Khoo, S. (2006). No room for complacency on drug resistance in Africa. Nature, 444(7115), 31.

Journal article

Pharmacogenetics of HIV therapy

Owen, A., Pirmohamed, M., Khoo, S. H., & Back, D. J. (2006). Pharmacogenetics of HIV therapy. Pharmacogenet Genomics, 16(10), 693-703. doi:10.1097/01.fpc.0000236338.41799.57

DOI
10.1097/01.fpc.0000236338.41799.57
Journal article

Pharmacokinetics of reverse transcriptase inhibitors

Hoggard, P., Kewn, S., Khoo, S., & Back, D. (2006). Pharmacokinetics of reverse transcriptase inhibitors. In G. Skowron, & R. Ogden (Eds.), Reverse Transcriptase Inhibitors in HIV/AIDS Therapy (pp. xxx). Totowa, New Jersey: Humana Press.

Chapter

Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.

Khoo, S. H., Lloyd, J., Dalton, M., Bonington, A., Hart, E., Gibbons, S., . . . Back, D. J. (2006). Pharmacological Optimization of PIs and NNRTIs (POPIN)- a randomised controlled trial of therapeutic drug monitoring and adherence support.. J Acquir Immune Defic Syndr, 41(4), 461-467.

Journal article

2005

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90.

Journal article

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Dickinson, L., Robinson, L., Tjia, J., Khoo, S., & Back, D. (2005). Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 829(1-2), 82-90. doi:10.1016/j.jchromb.2005.09.032

DOI
10.1016/j.jchromb.2005.09.032
Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. doi:10.1097/01.aids.0000194793.36175.40

DOI
10.1097/01.aids.0000194793.36175.40
Journal article

Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.

Sadiq, S. T., Fredericks, S., Khoo, S. H., Rice, P., & Holt, D. W. (2005). Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.. AIDS (London, England), 19(15), 1716-1717. doi:10.1097/01.aids.0000186828.99032.60

DOI
10.1097/01.aids.0000186828.99032.60
Journal article

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

Almond, L. M., Hoggard, P. G., Edirisinghe, D., Khoo, S. H., & Back, D. J. (2005). Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 56(4), 738-744. doi:10.1093/jac/dki308

DOI
10.1093/jac/dki308
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

DOI
10.1124/jpet.105.086272
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine.. The Journal of pharmacology and experimental therapeutics, 314(3), 1202-1209. doi:10.1124/jpet.105.086272

DOI
10.1124/jpet.105.086272
Journal article

Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

Bergshoeff, A., Burger, D., Verweij, C., Farrelly, L., Flynn, J., Le Prevost, M., . . . PENTA-13 Study Group. (2005). Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).. Antiviral therapy, 10(2), 239-246. doi:10.1177/135965350501000207

DOI
10.1177/135965350501000207
Journal article

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals

Almond, L. M., Edirisinghe, D., Dalton, M., Bonington, A., Back, D. J., & Khoo, S. H. (2005). Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2), 132-142. doi:10.1016/j.clpt.2005.04.004

DOI
10.1016/j.clpt.2005.04.004
Journal article

The potential for interactions between antimalarial and antiretroviral drugs.

Khoo, S., Back, D., & Winstanley, P. (2005). The potential for interactions between antimalarial and antiretroviral drugs.. AIDS (London, England), 19(10), 995-1005. doi:10.1097/01.aids.0000174445.40379.e0

DOI
10.1097/01.aids.0000174445.40379.e0
Journal article

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).

Gazzard, B., & BHIVA Writing Committee. (2005). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).. HIV medicine, 6 Suppl 2, 1-61. doi:10.1111/j.1468-1293.2005.0311b.x

DOI
10.1111/j.1468-1293.2005.0311b.x
Journal article

Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.

Hider, S. L., Hoggard, P., Khoo, S., Back, D., & Bruce, I. N. (2005). Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.. Arthritis and rheumatism, 52(2), 670. doi:10.1002/art.20770

DOI
10.1002/art.20770
Journal article

In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine

Owen, A., Janneh, O., Hartkoorn, R. C., Chandler, B., Bray, P. G., Martin, P., . . . Back, D. J. (2005). In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J Pharmacol Exp Ther, 314(3), 1202-1209.

Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16284458

Journal article

Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP

Janneh, O., Owen, A., Chandler, B., Hartkoorn, R. C., Hart, C. A., Bray, P. G., . . . Khoo, S. H. (2005). Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS, 19(18), 2097-2102.

Journal article

2004

The intracellular pharmacology of antiretroviral protease inhibitors

Ford, J., Khoo, S. H., & Back, D. J. (2004). The intracellular pharmacology of antiretroviral protease inhibitors. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(6), 982-990. doi:10.1093/jac/dkh487

DOI
10.1093/jac/dkh487
Journal article

Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4

Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D. J., & Khoo, S. H. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. JOURNAL OF VIROLOGY, 78(21), 12022-12029. doi:10.1128/JVI.78.21.12022-12029.2004

DOI
10.1128/JVI.78.21.12022-12029.2004
Journal article

Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA

Owen, A., Chandler, B., Back, D. J., & Khoo, S. H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. ANTIVIRAL THERAPY, 9(5), 819-821. Retrieved from https://www.webofscience.com/

Journal article

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

Isaac, A., Taylor, S., Cane, P., Smit, E., Gihbons, S. E., White, D. J., . . . Back, D. J. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 54(2), 498-502. doi:10.1093/jac/dkh357

DOI
10.1093/jac/dkh357
Journal article

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Ford, J., Boffito, M., Wildfire, A., Hill, A., Back, D., Khoo, S., . . . Pozniak, A. (2004). Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.. Antimicrobial agents and chemotherapy, 48(7), 2388-2393. doi:10.1128/aac.48.7.2388-2393.2004

DOI
10.1128/aac.48.7.2388-2393.2004
Journal article

The relationship between nevirapine plasma concentrations and abnormal liver function tests

Almond, L. M., Boffito, M., Hoggard, P. G., Bonora, S., Raiteri, R., Reynolds, H. E., . . . Di Perri, G. (2004). The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS RESEARCH AND HUMAN RETROVIRUSES, 20(7), 716-722. doi:10.1089/0889222041524670

DOI
10.1089/0889222041524670
Journal article

A British Second World War veteran with disseminated strongyloidiasis

Gill, G. V., Beeching, N. J., Khoo, S., Bailey, J. W., Partridge, S., Blundell, J. W., & Luksza, A. R. (2004). A British Second World War veteran with disseminated strongyloidiasis. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 98(6), 382-386. doi:10.1016/j.trstmh.2003.11.002

DOI
10.1016/j.trstmh.2003.11.002
Journal article

Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression

Ford, J., Cornforth, D., Hoggard, P. G., Cuthbertson, Z., Meaden, E. R., Williams, I., . . . Khoo, S. H. (2004). Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. ANTIVIRAL THERAPY, 9(1), 77-84. Retrieved from https://www.webofscience.com/

Journal article

Lopinavir protein binding in vivo through the 12-hour dosing interval

Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. THERAPEUTIC DRUG MONITORING, 26(1), 35-39. doi:10.1097/00007691-200402000-00008

DOI
10.1097/00007691-200402000-00008
Journal article

Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation.

Behzad-Behbahani, A., Klapper, P. E., Vallely, P. J., Cleator, G. M., & Khoo, S. H. (2004). Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridisation.. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 29(4), 224-229. doi:10.1016/s1386-6532(03)00155-0

DOI
10.1016/s1386-6532(03)00155-0
Journal article

Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4

Owen, A., Chandler, B., Bray, P. G., Ward, S. A., Hart, C. A., Back, D., & Khoo, S. (2004). Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol, 78(21), 12022-12029.

Journal article

Intracellular pharmacokinetics of antiretroviral agents.

Owen, A., & Khoo, S. H. (2004). Intracellular pharmacokinetics of antiretroviral agents.. Journal of HIV therapy, 9(4), 97-101.

Journal article

Lopinavir protein binding in vivo through the 12-hour dosing interval

Boffito, M., Hoggard, P. G., Lindup, W. E., Bonora, S., Sinicco, A., Khoo, S. H., . . . Back, D. J. (2004). Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit, 26(1), 35-39. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14749547

Journal article

Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen

Isaac, A., Taylor, S., Cane, P., Smit, E., Gibbons, S., White, D. J., . . . Back, D. (2004). Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother, 54(2), 498-502.

Journal article

Pharmacology update: drug-drug interactions and ethnic and sex differences

Back, D. J., Dickinson, L., Canta, F., & Khoo, S. (2004). Pharmacology update: drug-drug interactions and ethnic and sex differences. In HIV/AIDS Annual Update 2004. Clinical Care Options for HIV.

Chapter

Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.

Joseph, A. T., & Khoo, S. H. (2004). Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.. International journal of STD & AIDS, 15(1), 67-68. doi:10.1258/095646204322637335

DOI
10.1258/095646204322637335
Journal article

2003

Treating Advanced HIV Infection

Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating Advanced HIV Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 34(3), 344-345. doi:10.1097/00126334-200311010-00014

DOI
10.1097/00126334-200311010-00014
Journal article

Treating advanced HIV infection

Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S. H., . . . Di Perri, G. (2003). Treating advanced HIV infection. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 34(3), 344-345. doi:10.1097/00126334-200311010-00014

DOI
10.1097/00126334-200311010-00014
Journal article

Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines

Owen, A., Hartkoorn, R. C., Khoo, S., & Back, D. (2003). Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM<sub>VBL</sub>, CEM<sub>E1000</sub>, MDCKII<sub>MRP1</sub> and MDCKII<sub>MRP2</sub> cell lines. AIDS, 17(15), 2276-2278. doi:10.1097/00002030-200310170-00024

DOI
10.1097/00002030-200310170-00024
Journal article

Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes

Janneh, O., Haggard, P., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. ANTIVIRAL THERAPY, 8(5), 417-426. Retrieved from https://www.webofscience.com/

Journal article

Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting

Boffito, M., Bonora, S., Sales, P., Dal Conte, I., Sinicco, A., Hoggard, P. G., . . . Di Perri, G. (2003). Ketoconazole and lopinavir/ritonavir coadministration: Boosting beyond boosting. AIDS RESEARCH AND HUMAN RETROVIRUSES, 19(10), 941-942. doi:10.1089/088922203322493148

DOI
10.1089/088922203322493148
Journal article

Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression

Ford, J., Meaden, E. R., Hoggard, P. G., Dalton, M., Newton, P., Williams, I., . . . Back, D. J. (2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 52(3), 354-358. doi:10.1093/jac/dkg381

DOI
10.1093/jac/dkg381
Journal article

Pharmacokinetic drug interactions with nevirapine.

Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine.. Journal of acquired immune deficiency syndromes (1999), 34 Suppl 1, S8-14. doi:10.1097/00126334-200309011-00003

DOI
10.1097/00126334-200309011-00003
Journal article

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro

Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on P-glycoprotein expression in peripheral blood mononuclear cells in vitro. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 33(5), 551-556. doi:10.1097/00126334-200308150-00001

DOI
10.1097/00126334-200308150-00001
Journal article

Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.

Hennessy, M., Clarke, S., Spiers, J. P., Mulcahy, F., Kelleher, D., Meadon, E., . . . Barry, M. (2003). Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.. Antiviral therapy, 8(3), 191-198.

Journal article

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring

Boffito, M., Back, D. J., Hoggard, P. G., Caci, A., Bonora, S., Raiteri, R., . . . Di Perri, G. (2003). Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS, 17(7), 1107-1108. doi:10.1097/00002030-200305020-00029

DOI
10.1097/00002030-200305020-00029
Journal article

The role of clinical pharmacology in optimizing antiretroviral therapy

Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 55(5), 473-476. doi:10.1046/j.1365-2125.2003.01843.x

DOI
10.1046/j.1365-2125.2003.01843.x
Journal article

A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets

Ford, J., Hoggard, P. G., Owen, A., Khoo, S. H., & Back, D. J. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. JOURNAL OF IMMUNOLOGICAL METHODS, 274(1-2), 129-137. doi:10.1016/S0022-1759(02)00509-4

DOI
10.1016/S0022-1759(02)00509-4
Journal article

Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells

Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEM<sub>VBL</sub>, and CEM E<sub>1000</sub> cells. JOURNAL OF INFECTIOUS DISEASES, 187(5), 874-875. doi:10.1086/367902

DOI
10.1086/367902
Journal article

A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets

Ford, J., Hoggard, P. G., & et, A. (2003). A simplified approach to determining P-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods, 274(1-2), 129-137. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12609539

Journal article

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

Pozniak, A., Gazzard, B., Anderson, J., Babiker, A., Churchill, D., Collins, S., . . . BHIVA Writing Committee BHIVA Executive Committee. (2003). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.. HIV medicine, 4 Suppl 1, 1-41.

Journal article

Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells

Owen, A., Chandler, B., Ford, J., Khoo, S., & Back, D. (2003). Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells. J Infect Dis, 187(5). doi:10.1086/367902

DOI
10.1086/367902
Journal article

Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients

Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., . . . Back, D. J. (2003). Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 47(1), 255-261. doi:10.1128/AAC.47.1.255-261.2003

DOI
10.1128/AAC.47.1.255-261.2003
Journal article

Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes

Janneh, O., Hoggard, P. G., Tjia, J. F., Jones, S. P., Khoo, S. H., Maher, B., . . . Pirmohamed, M. (2003). Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther, 8(5), 417-426. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14640389

Journal article

Pharmacokinetic drug interactions with nevirapine

Back, D., Gibbons, S., & Khoo, S. (2003). Pharmacokinetic drug interactions with nevirapine. J Acquir Immune Defic Syndr, 34 Sup, S8-S14. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562853

Journal article

The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro

Chandler, B., Almond, L., Ford, J., Owen, A., Hoggard, P., Khoo, S., & Back, D. (2003). The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr, 33(5), 551-556. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12902797

Journal article

The role of clinical pharmacology in optimizing antiretroviral therapy

Back, D. J., & Khoo, S. H. (2003). The role of clinical pharmacology in optimizing antiretroviral therapy. Br J Clin Pharmacol, 55(5), 473-476. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12755810

Journal article

Therapeutic drug monitoring: help or hype?

Khoo, S. H. (2003). Therapeutic drug monitoring: help or hype?. In The strategic use of resistance data. Proceedings of the Six HIV Reistance Workshop. London: Mediscript.

Conference Paper

2002

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. doi:10.1097/00002030-200212060-00009

DOI
10.1097/00002030-200212060-00009
Journal article

Intracellular accumulation of human immunodeficiency virus protease inhibitors

Khoo, S. H., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. J. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(10), 3228-3235. doi:10.1128/AAC.46.10.3228-3235.2002

DOI
10.1128/AAC.46.10.3228-3235.2002
Journal article

P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals

Meaden, E. R., Hoggard, P. G., Newton, P., Tjia, J. F., Aldam, D., Cornforth, D., . . . Khoo, S. H. (2002). P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 50(4), 583-588. doi:10.1093/jac/dkf161

DOI
10.1093/jac/dkf161
Journal article

Therapeutic drug monitoring.

Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring.. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002), 1(3), 84-85. doi:10.1177/154510970200100301

DOI
10.1177/154510970200100301
Journal article

Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo

Meaden, E. R., Hoggard, P. G., Khoo, S. H., & Back, D. J. (2002). Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. JOURNAL OF IMMUNOLOGICAL METHODS, 262(1-2), 159-165. doi:10.1016/S0022-1759(02)00020-0

DOI
10.1016/S0022-1759(02)00020-0
Journal article

Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients

Kewn, S., Hoggard, P. G., Sales, S. D., Jones, K., Maher, B., Khoo, S. H., & Back, D. J. (2002). Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 46(1), 135-143. doi:10.1128/AAC.46.1.135-143.2002

DOI
10.1128/AAC.46.1.135-143.2002
Journal article

Intracellular accumulation of human immunodeficiency virus protease inhibitors

Khoo, S., Hoggard, P. G., Williams, I., Meaden, E. R., Newton, P., Wilkins, E. G., . . . Back, D. (2002). Intracellular accumulation of human immunodeficiency virus protease inhibitors. Antimicrob Agents Chemother, 46(10), 3228-3235.

Journal article

Pharmacology

Khoo, S., Back, D. J., & Merry, C. (2002). Pharmacology. In C. A. B. Boucher, & G. Galasso (Eds.), Practical guidelines in antiviral therapy (pp. vii, 344 p.). Amsterdam ; London: Elsevier.

Chapter

Therapeutic drug monitoring

Back, D., Khoo, S., & Gibbons, S. (2002). Therapeutic drug monitoring. J Int Assoc Physicians AIDS Care (Chic), 1(3), 84-85.

Journal article

Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea

Hoggard, P. G., Kewn, S., Maherbe, A., Wood, R., Almond, L. M., Sales, S. D., . . . Khoo, S. H. (2002). Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. AIDS, 16(18), 2439-2446. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12461418

Journal article

2001

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

BHIVA Writing Committee., & BHIVA Executive Committee. (2001). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.. HIV medicine, 2(4), 276-313. doi:10.1046/j.1464-2662.2001.00083.x

DOI
10.1046/j.1464-2662.2001.00083.x
Journal article

Therapeutic drug monitoring as a tool in treating HIV infection

Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15, S171-S181. doi:10.1097/00002030-200100005-00021

DOI
10.1097/00002030-200100005-00021
Journal article

Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i>

Sales, S. D., Hoggard, P. G., Sunderland, D., Khoo, S., Hart, C. A., & Back, D. J. (2001). Zidovudine phosphorylation and mitochondrial toxicity <i>in vitro</i>. TOXICOLOGY AND APPLIED PHARMACOLOGY, 177(1), 54-58. doi:10.1006/taap.2001.9288

DOI
10.1006/taap.2001.9288
Journal article

Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients

Meaden, E. R., Hoggard, P. G., Maher, B., Khoo, S. H., & Back, D. J. (2001). Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS RESEARCH AND HUMAN RETROVIRUSES, 17(14), 1329-1332. doi:10.1089/08892220152596588

DOI
10.1089/08892220152596588
Journal article

The role of therapeutic drug monitoring in treatment of HIV infection

Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 52, 89S-96S. Retrieved from https://www.webofscience.com/

Journal article

P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

Jones, K., Bray, P. G., Khoo, S. H., Davey, R. A., Meaden, E. R., Ward, S. A., & Back, D. J. (2001). P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. AIDS, 15(11), 1353-1358. doi:10.1097/00002030-200107270-00004

DOI
10.1097/00002030-200107270-00004
Journal article

The role of therapeutic drug monitoring in treatment of HIV infection

Back, D. J., Khoo, S. H., Gibbons, S. E., & Merry, C. (2001). The role of therapeutic drug monitoring in treatment of HIV infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(4), 301-308. doi:10.1046/j.1365-2125.2001.01380.x

DOI
10.1046/j.1365-2125.2001.01380.x
Journal article

Novel IFN-alpha receptor promoter polymorphisms.

Muldoon, J., Uriel, A., Khoo, S., Ollier, W. E., & Hajeer, A. H. (2001). Novel IFN-alpha receptor promoter polymorphisms.. Genes and immunity, 2(3), 159-160. doi:10.1038/sj.gene.6363757

DOI
10.1038/sj.gene.6363757
Journal article

Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport

Jones, K., Hoggard, P. G., Sales, S. D., Khoo, S., Davey, R., & Back, D. J. (2001). Differences in the intracellular accumulation of HIV protease inhibitors <i>in vitro</i> and the effect of active transport. AIDS, 15(6), 675-681. doi:10.1097/00002030-200104130-00002

DOI
10.1097/00002030-200104130-00002
Journal article

Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents

Hoggard, P. G., Lloyd, J., Khoo, S. H., Barry, M. G., Dann, L., Gibbons, S. E., . . . Back, D. J. (2001). Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(3), 976-980. doi:10.1128/AAC.35.3.976-980.2001

DOI
10.1128/AAC.35.3.976-980.2001
Journal article

Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>

Jones, K., Hoggard, P. G., Khoo, S., Maher, B., & Back, D. J. (2001). Effect of α<sub>1</sub>-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir <i>in vitro</i>. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51(1), 99-102. doi:10.1046/j.1365-2125.2001.01324.x

DOI
10.1046/j.1365-2125.2001.01324.x
Journal article

Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo

Hoggard, P. G., Sales, S. D., Phiboonbanakit, D., Lloyd, J., Maher, B. A., Khoo, S. H., . . . Back, D. J. (2001). Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 45(2), 577-582. doi:10.1128/AAC.45.2.577-582.2001

DOI
10.1128/AAC.45.2.577-582.2001
Journal article

Therapeutic drug monitoring as a tool in treating HIV infection

Khoo, S. H., Gibbons, S. E., & Back, D. J. (2001). Therapeutic drug monitoring as a tool in treating HIV infection. AIDS, 15 Sup, S171-S181. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11816166

Journal article

Therapeutic drug monitoring of anti-HIV drugs

Back, D. J., Khoo, S. H., Gibbons, S. E., Reynolds, H., Tjia, J. F., & Merry, C. (2001). Therapeutic drug monitoring of anti-HIV drugs. OPTIMAL DOSE IDENTIFICATION, 1220, 145-160. doi:10.1016/S0531-5131(01)00294-1

DOI
10.1016/S0531-5131(01)00294-1
Journal article

2000

Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers

Wattanagoon, Y., Bangchang, K. N., Hoggard, P. G., Khoo, S. H., Gibbons, S. E., Phiboonbhanakit, D., . . . Back, D. J. (2000). Pharmacokinetics of zidovudine phosphorylation in human immunodeficiency virus-positive Thai patients and healthy volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 44(7), 1986-1989. doi:10.1128/AAC.44.7.1986-1989.2000

DOI
10.1128/AAC.44.7.1986-1989.2000
Journal article

Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection

Back, D. J., Khoo, S. H., Gibbons, S. E., Barry, M. G., & Merry, C. (2000). Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. THERAPEUTIC DRUG MONITORING, 22(1), 122-126. doi:10.1097/00007691-200002000-00026

DOI
10.1097/00007691-200002000-00026
Journal article

Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i>

Hoggard, P. G., Sales, S. D., Kewn, S., Sunderland, D., Khoo, S. H., Hart, C. A., & Back, D. J. (2000). Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression <i>in vitro</i>. ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 11(6), 353-358. doi:10.1177/095632020001100601

DOI
10.1177/095632020001100601
Journal article

Current uses and future hopes for clinical pharmacology in the management of HIV infection

Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection. HIV Med, 1 Supp, 12-17. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11737367

Journal article

Current uses and future hopes for clinical pharmacology in the management of HIV infection.

Back, D., Khoo, S., Maher, B., & Gibbons, S. (2000). Current uses and future hopes for clinical pharmacology in the management of HIV infection.. HIV medicine, 1 Suppl 2, 12-17. doi:10.1046/j.1468-1293.2000.00001.x

DOI
10.1046/j.1468-1293.2000.00001.x
Journal article

Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients.

Lord, A., Bailey, A. S., Klapper, P. E., Snowden, N., & Khoo, S. H. (2000). Impaired humoral responses to subgenus D adenovirusenovirus infections in HIV-positive patients.. Journal of medical virology, 62(4), 405-409. doi:3.0.co;2-8">10.1002/1096-9071(200012)62:4<405::aid-jmv2>3.0.co;2-8

DOI
10.1002/1096-9071(200012)62:4<405::aid-jmv2>3.0.co;2-8
Journal article

Management of HIV infection in adults

Khoo, S. H., & Wilkins, E. G. L. (2000). Management of HIV infection in adults. Prescribers' Journal, 40(1), 10-19.

Journal article

1999

The management of Pneumocystis carinii pneumonia.

Vilar, F. J., Khoo, S. H., & Walley, T. (1999). The management of Pneumocystis carinii pneumonia.. British journal of clinical pharmacology, 47(6), 605-609. doi:10.1046/j.1365-2125.1999.00966.x

DOI
10.1046/j.1365-2125.1999.00966.x
Journal article

Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.

De Jong, J. C., Wermenbol, A. G., Verweij-Uijterwaal, M. W., Slaterus, K. W., Wertheim-Van Dillen, P., Van Doornum, G. J., . . . Hierholzer, J. C. (1999). Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.. Journal of clinical microbiology, 37(12), 3940-3945. doi:10.1128/jcm.37.12.3940-3945.1999

DOI
10.1128/jcm.37.12.3940-3945.1999
Journal article

1998

Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections.

Khoo, S. H., Hajia, M., Storey, C. C., Klapper, P. E., Wilkins, E. G., Denning, D. W., . . . Mandal, B. K. (1998). Influenza-like episodes in HIV-positive patients: the role of viral and 'atypical' infections.. AIDS (London, England), 12(7), 751-757.

Journal article

1997

In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy

Veal, G. J., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). In vitro screening of nucleoside analog combinations for potential use in anti-HIV therapy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 13(6), 481-484. doi:10.1089/aid.1997.13.481

DOI
10.1089/aid.1997.13.481
Journal article

The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.

Ng, T. T., Kanner, S. B., Humphries, M. J., Wickremasinghe, R. G., Nye, K. E., Anderson, J., . . . Morrow, W. J. (1997). The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.. Journal of immunology (Baltimore, Md. : 1950), 158(6), 2984-2999.

Journal article

Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression.

Khoo, S. H., Pepper, L., Snowden, N., Hajeer, A. H., Vallely, P., Wilkins, E. G., . . . Ollier, W. E. (1997). Tumour necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression.. AIDS (London, England), 11(4), 423-428. doi:10.1097/00002030-199704000-00004

DOI
10.1097/00002030-199704000-00004
Journal article

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

Hoggard, P. G., Kewn, S., Barry, M. G., Khoo, S. H., & Back, D. J. (1997). Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 41(6), 1231-1236. doi:10.1128/AAC.41.6.1231

DOI
10.1128/AAC.41.6.1231
Journal article

1996

Intracellular metabolism of zidovudine and stavudine in combination.

Hoggard, P., Khoo, S., Barry, M., & Back, D. (1996). Intracellular metabolism of zidovudine and stavudine in combination.. The Journal of infectious diseases, 174(3), 671-672. doi:10.1093/infdis/174.3.671

DOI
10.1093/infdis/174.3.671
Journal article

Induction of adrenal suppression by megestrol acetate.

Stoffer, S. S., & Krakauer, J. C. (1996). Induction of adrenal suppression by megestrol acetate.. Annals of internal medicine, 124(6), 613-614. doi:10.7326/0003-4819-124-6-199603150-00018

DOI
10.7326/0003-4819-124-6-199603150-00018
Journal article

Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation

Veal, G. J., Hoggard, P. G., Barry, M. G., Khoo, S., & Back, D. J. (1996). Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation. AIDS, 10(5), 546-548. doi:10.1097/00002030-199605000-00016

DOI
10.1097/00002030-199605000-00016
Journal article

Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency

Pirmohamed, M., Williams, D., Tingle, M. D., Barry, M., Khoo, S. H., OMahony, C., . . . Park, B. K. (1996). Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency. AIDS, 10(5), 501-507. doi:10.1097/00002030-199605000-00008

DOI
10.1097/00002030-199605000-00008
Journal article

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8902065

Journal article

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

Barry, M. G., Khoo, S. H., Veal, G. J., Hoggard, P. G., Gibbons, S. E., Wilkins, E. G. L., . . . Back, D. J. (1996). The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS, 10(12), 1361-1367. doi:10.1097/00002030-199610000-00008

DOI
10.1097/00002030-199610000-00008
Journal article

1995

Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology.

Khoo, S. H., Bailey, A. S., de Jong, J. C., & Mandal, B. K. (1995). Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology.. The Journal of infectious diseases, 172(3), 629-637. doi:10.1093/infdis/172.3.629

DOI
10.1093/infdis/172.3.629
Journal article

MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS

WINSTANLEY, P., KHOO, S., SZWANDT, S., EDWARDS, G., WILKINS, E., TIJA, J., . . . BRECKENRIDGE, A. (1995). MARKED VARIATION IN PYRIMETHAMINE DISPOSITION IN AIDS PATIENTS TREATED FOR CEREBRAL TOXOPLASMOSIS. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 36(2), 435-439. doi:10.1093/jac/36.2.435

DOI
10.1093/jac/36.2.435
Journal article

Safety and efficacy of combined meningococcal and typhoid vaccine.

Khoo, S. H., St Clair Roberts, J., & Mandal, B. K. (1995). Safety and efficacy of combined meningococcal and typhoid vaccine.. BMJ (Clinical research ed.), 310(6984), 908-909. doi:10.1136/bmj.310.6984.908

DOI
10.1136/bmj.310.6984.908
Journal article

Controversies in anti-retroviral therapy of adults.

Khoo, S. H., & Wilkins, E. G. (1995). Controversies in anti-retroviral therapy of adults.. The Journal of antimicrobial chemotherapy, 35(2), 245-262. doi:10.1093/jac/35.2.245

DOI
10.1093/jac/35.2.245
Journal article

Cure of chronic invasive sinus aspergillosis with oral saperconazole.

Khoo, S. H., & Denning, D. W. (1995). Cure of chronic invasive sinus aspergillosis with oral saperconazole.. Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology, 33(1), 63-66. doi:10.1080/02681219580000131

DOI
10.1080/02681219580000131
Journal article

Prevalence of cortisol deficiency in late HIV disease.

Abbott, M., Khoo, S. H., Hammer, M. R., & Wilkins, E. G. (1995). Prevalence of cortisol deficiency in late HIV disease.. The Journal of infection, 31(1), 1-4. doi:10.1016/s0163-4453(95)91116-2

DOI
10.1016/s0163-4453(95)91116-2
Journal article

1994

Invasive aspergillosis in patients with AIDS.

Khoo, S. H., & Denning, D. W. (1994). Invasive aspergillosis in patients with AIDS.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 19 Suppl 1, S41-S48. doi:10.1093/clinids/19.supplement_1.s41

DOI
10.1093/clinids/19.supplement_1.s41
Journal article

Administering amphotericin B--a practical approach.

Khoo, S. H., Bond, J., & Denning, D. W. (1994). Administering amphotericin B--a practical approach.. The Journal of antimicrobial chemotherapy, 33(2), 203-213. doi:10.1093/jac/33.2.203

DOI
10.1093/jac/33.2.203
Journal article

1993

Serum measurements of soluble CD23 in HIV infection.

Bansal, A. S., Pumphrey, R. S., Mandal, B. K., Khoo, S. H., & Wilson, P. B. (1993). Serum measurements of soluble CD23 in HIV infection.. Immunology, 80(4), 652-653.

Journal article

1992

Time to finish with "AIDS"?

Khoo, S. H., Bailey, G., Wilkins, E. G., & Denning, D. W. (1992). Time to finish with "AIDS"?. Lancet (London, England), 339(8804), 1298. doi:10.1016/0140-6736(92)91628-l

DOI
10.1016/0140-6736(92)91628-l
Journal article

Fulminant community acquired infections admitted to an intensive care unit

Khoo, S. H., Creagh-Barry, P., Wilkins, E. G., & Pasvol, G. (1992). Fulminant community acquired infections admitted to an intensive care unit. Q J Med, 83(301), 381-388. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1438673

Journal article

Fulminant community acquired infections admitted to an intensive care unit.

Khoo, S. H., Creagh-Barry, P., Wilkins, E. G., & Pasvol, G. (1992). Fulminant community acquired infections admitted to an intensive care unit.. The Quarterly journal of medicine, 83(301), 381-388.

Journal article

Reactivation of tuberculous lymphadenitis during pregnancy.

Warner, T. T., Khoo, S. H., & Wilkins, E. G. (1992). Reactivation of tuberculous lymphadenitis during pregnancy.. The Journal of infection, 24(2), 181-184. doi:10.1016/0163-4453(92)92928-c

DOI
10.1016/0163-4453(92)92928-c
Journal article

1991

Tuberculous pericarditis confirmed by DNA amplification.

Godfrey-Faussett, P., Wilkins, E. G., Khoo, S., & Stoker, N. (1991). Tuberculous pericarditis confirmed by DNA amplification.. Lancet (London, England), 337(8734), 176-177. doi:10.1016/0140-6736(91)90840-l

DOI
10.1016/0140-6736(91)90840-l
Journal article

Multiple episodes of bacterial endocarditis occurring over 9 years.

Khoo, S. H., & Larson, H. E. (1991). Multiple episodes of bacterial endocarditis occurring over 9 years.. The Journal of infection, 22(3), 263-268. doi:10.1016/s0163-4453(05)80009-x

DOI
10.1016/s0163-4453(05)80009-x
Journal article

Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment].

Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . Larson, E. (1991). Northwick Park Infection Consultation Service. Part I. The aims and operation of the service and the general distribution of infection identified by the service between September 1987 and July 1990 [see comment].. The Journal of infection, 23(1), 47-56. doi:10.1016/0163-4453(91)94041-h

DOI
10.1016/0163-4453(91)94041-h
Journal article

Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990.

Wilkins, E. G., Hickey, M. M., Khoo, S., Hale, A. D., Umasankar, S., Thomas, P., . . . Larson, E. (1991). Northwick Park Infection Consultation Service. Part II. Contribution of the service to patient management: an analysis of results between September 1987 and July 1990.. The Journal of infection, 23(1), 57-63. doi:10.1016/0163-4453(91)94063-p

DOI
10.1016/0163-4453(91)94063-p
Journal article

Severe Helicobacter pylori infection in a patient with AIDS.

Khoo, S. H., & Blackwell, N. (1991). Severe Helicobacter pylori infection in a patient with AIDS.. AIDS (London, England), 5(10), 1253-1255. doi:10.1097/00002030-199110000-00016

DOI
10.1097/00002030-199110000-00016
Journal article

Severe hyponatraemia in malaria.

Khoo, S. H., & Wilkins, E. G. (1991). Severe hyponatraemia in malaria.. The Journal of infection, 23(1), 85-87. doi:10.1016/0163-4453(91)94195-p

DOI
10.1016/0163-4453(91)94195-p
Journal article

Undated